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Antimicrobial resistance (AMR) is fast becoming one of the greatest challenges to 
human mortality this century. In recent years the number of reported infections by 
multi-drug resistant (MDR) bacteria has seen a rapid rise. As a result, the efficacy of 
currently used antibiotics is decreasing, with infections by MDR bacteria increasingly 
difficult to treat. In more and more cases, the use of last-line drugs is becoming 
necessary. However, this in turn has resulted in increasing reports of last-line drug 
resistance, presenting a dangerous cycle that leaves us potentially short of 
treatment options. As a result, elucidating the intrinsic resistance mechanisms that 
pathogens employ, and their importance in generating an AMR phenotype, is 
essential to developing a comprehensive and effective antimicrobial strategy. 
Furthermore, identifying specific resistance mechanisms and their contribution to 
AMR presents potential targets for inhibitory drugs in combination with existing 
antimicrobials. 
This project looks at the role of the transcription regulator RamA in generating an 
AMR phenotype in the Gram-negative bacterium Klebsiella pneumoniae. K. 
pneumoniae is a major cause of nosocomial infections in the immunocompromised, 
with MDR isolates resistant to the last-line drug colistin rapidly increasing in 
prevalence. K. pneumoniae RamA regulates genes associated with virulence and 
resistance, able to modulate outer membrane permeability through altered influx and 
efflux. Overexpression of ramA has also been shown to upregulate the dioxygenase 
LpxO, a lipid A modifying enzyme associated with increased resistance to colistin, 
polymyxin B, and the human cationic antimicrobial peptide LL-37. Our study seeks 
to define the relative importance of RamA and LpxO in relation to polymyxin B, 
colistin and LL-37; specifically how RamA-mediated lpxO-overexpression confers 
this phenotype. In this regard, we have performed MIC and relative survival assay 
studies with wild-type K. pneumoniae, ramA- and lpxO-overexpressing strains, in 
order to define the role of these genes in the relevant phenotypes. 
 
 





Antimicrobial resistance (AMR) is an immediate danger to public health worldwide, 
threatening the delivery of effective treatment against a range of infectious diseases. 
Due to the rapid development of resistance among pathogens, we are stumbling into 
a situation where demand for effective treatment outweighs supply; where without a 
change of strategy, currently routine surgeries will soon present high risk of 
potentially lethal infection.  
The bacterium Klebsiella pneumoniae is a major cause of respiratory and blood 
stream infections in long-term healthcare settings. It is an increasingly important 
pathogen worldwide due to the emergence of multi-drug resistant strains capable of 
surviving in the face of antimicrobial treatment.  Significantly, strains have recently 
been identified that are resistant to colistin, a “last-resort” drug used to treat already 
resistant infections.  
Our project focuses on intrinsic resistance in K. pneumoniae; the ability of the 
bacterium to develop resistance under antimicrobial pressure due to inherent 
structural and functional properties. RamA is an intrinsic K. pneumoniae protein, 
previously demonstrated to drive alterations to the bacterial surface and affect 
bacterial permeability. This prevents antimicrobial recognition, binding, and cell entry 
by host immune factors and antibiotic drugs. LpxO is an enzyme capable of 
changing outer membrane structure, linked with increased survival after 
antimicrobial challenge. Whilst its activity has been shown to be regulated by RamA, 
other factors also influence its control. 
The roles of RamA and LpxO in AMR are important for bacterial infection and 
resistance to antibiotics. Our work looks to define the relative importance of RamA 
and LpxO in contributing to K. pneumoniae AMR; to better understand how RamA 
controls the lpxO gene to modify the cell surface of K. pneumoniae.  
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Key of abbreviations 
 
 Δ = deletion (for example: “ΔlpxO” 
corresponds to a “lpxO deletion” 
 <>Km = gene replaced by a Km 
cassette (for example: 
“<lpxO>Km” means that the lpxO 
gene has been replaced by a Km 
cassette) 
 3GC = third-generation 
cephalosporins 
 Amp = ampicillin 
 AMR = antimicrobial resistance 
 bp = base pairs 
 CAMP = (cationic antimicrobial 
peptide) 
 Cm = chloramphenicol 
 FRT = Flp recognition target 
 IM = inner membrane 
 Km = kanamycin 
 LPS = lipopolysaccharide 
 MBL = metallo-beta-lactamase  
 MDR = multi-drug 
resistance/resistant 
 MIC = minimum inhibitory 
concentration 
 MW = molecular weight 
 OM = outer membrane 
 PAMP = pathogen-associated 
molecular pattern 
 PRR = pattern recognition 
receptor 
 PxB = polymyxin B 
 R = resistance/resistant (for 
example: “KmR” refers to 
kanamycin resistance or a 
kanamycin-resistant gene) 
 RSA = relative survival assay 
 S = sensitivity/sensitive (for 
example: “KmS” means either 
kanamycin sensitivity or a 
kanamycin-sensitive gene 
 sdH2O = sterile distilled water 
 SN = supernatant 
 spp. = species 
 Tc = tetracycline 
 TCS = two-component system 
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1.1. Antimicrobial Resistance: a Global Crisis 
Antimicrobial resistance (AMR) presents an immediate danger to global public 
health, threatening the delivery of effective prevention and treatment to a broad 
range of infectious diseases. Antimicrobial drug development has failed to keep 
pace with a constantly evolving assortment of resistant pathogens, leading to limited 
options for patient treatment [6]. In the absence of effective antimicrobials, the ability 
to conduct currently routine surgeries will be severely compromised, whilst young, 
healthy individuals will find themselves vulnerable to what were previously easily 
treatable infections. On our current heading, and without a concerted change of 
strategy, we are facing a post-antimicrobial period in which common infections will 
pose a high risk of death. 
1.1.1. An overview of AMR 
Beginning with the original discovery and development of antimicrobials, the fight 
against pathogens and infectious diseases took a major swing in favour of public 
health. Many infections with previously deadly pathogens quickly became easily 
treatable [7, 8]. Penicillin for example, discovered in 1928 by Alexander Fleming [9], 
became a commonly used treatment against Staphylococcus aureus infection after 
World War II [8]. Nonetheless, as soon as the early 1950s, penicillin-resistant S. 
aureus strains had emerged that were being regularly isolated in clinical settings [8].  
Resistance of pathogens to antimicrobials is a natural process occurring over time, 
part of the evolutionary development by which these organisms persist and survive 
in the face of selective pressure from unfavourable environments. However, 
constant exposure to antimicrobials leads to continual selective pressure, 
accelerating the evolution of resistance by forcing pathogens to adapt and survive 
[10]. In recent decades, due to widespread use and misuse of antimicrobial drugs in 
human healthcare [11], as well as animal management and food production [12, 13], 
the threat of AMR has emerged as a major and immediate public health crisis. 
One of the key factors contributing to AMR is antimicrobial use in animal husbandry. 
Globally, it has been estimated that two thirds of all antibacterial drugs produced 
each year are used in animal care [14]. They are often applied as metaphylactics en 
masse to livestock at the first sign of illness [15], and this liberal distribution is likely 
an important contributor to the selection and spread of environmental AMR [16]. 
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Especially worrying is that the classes of antibacterial drugs administered in animal 
care include all those important for human medicine [17], whilst some agents used 
are considered by the World Health Organisation (WHO) to be of critical importance 
to humans [18].  
One of the major challenges accompanying increasing rates of AMR is changing 
global demographics: populations are ageing, leading to a greater number of people 
with weakened immune systems, the body’s first and most effective defence against 
infection [19]. The elderly also tend to suffer more from co-morbidities, resulting in 
an increased vulnerability to infection; even from non-resistant pathogens and when 
effective antimicrobials are still available. As resistant pathogens become a regular 
occurrence and existing drugs become less successful at clearing infection, these 
populations will face an even bigger risk of serious illness. 
Furthermore, with a greater prevalence of AMR comes a significant threat to the 
ability to deliver commonplace health services. Antimicrobials are essential 
prophylactics and treatments used to quickly and effectively protect from and fight 
infections; preventing the onset of potentially fatal diseases in vulnerable patients 
and allowing operations to be performed with low risk of infection [20]. They are 
essential for routine surgeries, such as caesarean sections or hip replacements, to 
protect patients against infection. They are also a fundamental component of 
chemotherapy for cancer treatment and organ transplants, due to the treatment’s 
need to repress the body’s immune system and therefore remove its inherent, 
natural defence. As these antimicrobials become ever more ineffective at battling 
resistant infections, the risks associated with previously everyday treatments and 
surgeries will become too high.  
Worryingly, we are reaching a point where even resistance to last-line drugs is 
beginning to emerge [20]. These are antimicrobial drugs used as a last resort 
provided all other options have been exhausted, which are both expensive and often 
accompanied by adverse side effects. A report from January 2017 stresses the 
significance of the escalating nature of AMR: an elderly patient in the United States 
who died in September 2016 of septic shock was infected with a strain of bacteria 
resistant to all antimicrobial drugs available, including last-line drugs [21].  
 The ability of pathogens to acquire cross-resistance to host immune defences and 
antimicrobial drugs is also an alarming prospect [22-24]. Healthy, young populations 
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Figure 1. Numbers of attributable deaths per year compared between different causes. 
Currently, AMR is estimated to result in 700,000 deaths per year; a significant figure but one 
which pales in comparison to fatalities from cancer. If strategies to combat AMR remain 
unchanged, it is estimated to lead to approximately 10 million deaths per year by 2050. 
Adapted from the Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a 
Crisis for the Health and Wealth of Nations. 2014 [3]. 
with fully functioning immune systems may have to face the possibility of potentially 
debilitating disease as a result of previously treatable infections. When all of these 
factors are taken into consideration, it is easy to see how the estimated numbers of 
global deaths caused by AMR annually rises from seven hundred thousand at 
present to approximately ten million by 2050 [3] (Figure 1). As a result, a 
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Figure 2. Predicted cumulative world GDP loss in US$ trillions as a result of AMR. The 
steadily accumulating global GDP loss, represented by the shaded blue area, conservatively 
estimates that by 2050 the global economy stands to lose approximately US$100.2 trillion as 
a result of AMR. Higher risk of infection may lead to rejection of surgical operations; 
reductions in tourism and trade might result from global transmission fears; decreased 
efficacy of current drugs could lead to reduced purchase and use. Adapted from the Review 
on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health 
and Wealth of Nations. 2014 [3]. 
1.1.2. Economic fallout from AMR 
The rapid emergence of AMR has had impacts beyond solely patient welfare; the 
economic effects are also considerable (Figure 2). Patients suffering resistant 
infections are hospitalised for longer, draining medical resources and potentially 
requiring more costly medical interventions. A major reason for rising costs is 
treatment failure, often caused initially by sub-optimal dosing or incorrect diagnoses. 
Increasingly, doctors are turning to last-line drugs to treat resistant infections. These 
are more expensive, have greater adverse effects, and may be inaccessible in 
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Economic productivity is also indirectly affected by sick leave; the lengthier 
hospitalisation of workers due to resistant infections causes a knock-on effect on 
economic output. Although this particular argument should be considered in context 
– the majority of resistant infections occur in the elderly and those with co-
morbidities, patients who are unlikely to be contributing significantly to the workforce 
[25] – the combination of these factors considerably influences the direct and 
indirect impact of AMR on more than just public health.  
1.1.3. Investment in AMR research is essential 
There is an urgent need for greater investment into novel research to better 
understand the development of resistance in pathogens, optimise existing 
antimicrobials, and develop new medicines and preventative measures with which to 
strengthen global health systems. However, in recent decades there have been no 
significant new drug discoveries (Figure 3), and currently there are very few novel 
drugs in the development pipeline, with economic incentives for large 
pharmaceutical companies lacking [26]. Indeed, a look at the March 2016 product 
pipeline for GlaxoSmithKline indicates that of the approximately one hundred 
pharmaceuticals and vaccines in development, fourteen are related to HIV and 
infectious diseases, and only one is for the treatment of bacterial infections [27]. 
Furthermore, Pfizer’s pipeline lists a total of 94 products as of November 2016, but 
no antimicrobial drugs in development [28]. 
Bridging the gap between preclinical and clinical development is an area of concern 
for many drug companies; costly and highly-regulated clinical trials may fail or simply 
not meet the regulatory requirements imposed, whilst the short-term dosing of most 
antimicrobials, and the requirement for inexpensiveness and limited application, 
means returns on investment are lower than most chronic disease medications [29, 
30]. Consequently, investment in antimicrobial development has faltered, thereby 





P a g e  | 17 
 
  
Figure 3. Discovery timeline of distinct antibacterial drug classes. In recent decades 
there has been a dearth of research and investment by major pharmaceutical companies 
into novel antibacterial drugs, with no new drug classes identified and developed since 1987. 
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1.2. Klebsiella pneumoniae 
Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative rod-shaped bacterium 
belonging to the family Enterobacteriaceae, which also includes pathogens such as 
Escherichia coli (E. coli) and Salmonella species (spp.). Members of the 
Enterobacteriaceae family typically reside as part of the gut microbiota of humans 
and animals [31-33], whilst some can reside naturally in the environment [34-37]. 
Some Enterobacteriaceae are opportunistic pathogens, and under certain 
circumstances where the host has weakened immune defences these bacteria can 
exploit vulnerabilities and cause disease [31, 38, 39]. The rise of multi-drug resistant 
(MDR) Enterobacteriaceae has been recognised by the Centers for Disease Control 
and Prevention (CDC). In 2013 the CDC released a report – “Antibiotic Resistance 
Threats” – which labelled MDR-Enterobacteriaceae, including MDR-K. pneumoniae, 
as posing an urgent threat level to human health [11]. 
K. pneumoniae is found ubiquitously in both the environment, where isolates have 
been described as being as virulent as human clinical isolates [36, 40, 41], and in 
humans, where it forms a part of the normal microbiota of the human gastrointestinal 
(GI) tract. Clinically it is the most significant member of the Klebsiella genus, 
commonly causing nosocomial infections in long-term healthcare settings [42-44]. K. 
pneumoniae is responsible for infections of the urinary tract (UTI), wounds and 
surgical sites, with the potential to also cause life-threatening bacteraemia and 
pneumonia [42, 45]. Infections are typically seen in vulnerable patients such as the 
elderly, immunocompromised, and patients already suffering co-morbidities [45]. 
Patients in intensive care units and long-term nursing homes, post-surgery patients 
and those with invasive medical devices are particularly vulnerable [45], whilst 
exposure to antimicrobial treatment for a prolonged period of time is also a risk 
factor [46, 47].  
K. pneumoniae commonly colonises the GI tract, which forms a reservoir for the 
spread of K. pneumoniae in healthcare environments, and also acts as a potential 
source of infection for the host further down the line [48]. In addition, studies have 
found the presence of K. pneumoniae on a variety of hospital equipment, ranging 
from bed rails, mattresses and television monitors, to endotracheal tubes and 
duodenoscopes [49-54]. This represents a further potential source of infection, and 
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as a result, adherence to strict infection control and prevention practices is essential 
to reduce transmission of K. pneumoniae and improve infection rates [55]. 
1.2.1. Severity and implications of K. pneumoniae AMR 
Treating K. pneumoniae infection is difficult and clearance often requires 
administering antimicrobials [47, 56, 57]. However, a key characteristic of K. 
pneumoniae is its ability to quickly develop resistance in vivo to a broad range of 
antimicrobials [46, 57-59]. This has severe implications for vulnerable patients with 
weakened immune defences, such as those with underlying illnesses, the elderly or 
the young. Without the support of effective antimicrobial treatment, infections with 
MDR K. pneumoniae are particularly troublesome [45]. Furthermore, due to the 
variety of ways in which K. pneumoniae can persist in the hospital environment [49-
52], there is a real threat of nosocomial outbreaks, with vulnerable patients in 
particular at risk of hospital-acquired MDR infection [45]. Infections with MDR K. 
pneumoniae dramatically increase the likelihood of death, with mortality rates in 
excess of 50% [11, 48]. 
The development of AMR in K. pneumoniae and other Enterobacteriaceae follows a 
repetitive pattern: once a new and effective drug is developed, resistance quickly 
emerges [10, 60]. This is followed by a scramble to identify new drugs or modify 
existing agents, administer them with initial success, then watch as resistance again 
develops. This has led to the emergence of numerous K. pneumoniae strains with a 
variety of resistance mechanisms, with the ability to spread globally at a rapid rate.  
1.2.2. Mechanisms of acquired resistance in K. pneumoniae and global 
significance 
The ability of bacteria to acquire resistance is a common cause of emerging MDR 
strains. It can arise from spontaneous mutations as a result of selective pressure, 
where competition for survival under antimicrobial challenge forces only resistant 
bacteria to survive, or exposure to mutagenizing factors [61]. Mutations can have 
various ramifications, such as the over-expression of resistance-conferring genes, or 
alterations to antimicrobial targets which prevent drug recognition and binding [61]. 
Alternatively, resistance traits can develop through the acquisition of foreign 
resistance genes via horizontal gene transfer. This can prove particularly 
challenging to diagnostics and treatment due to the indiscriminate nature of 
horizontal gene transfer. Resistance genes borne on mobile genetic elements can 
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pass between bacteria of different species, leading to rapid development of novel 
forms of resistance [62]. The use of antimicrobials also drives the development of 
AMR by removing drug-sensitive competitors – both commensal and disease-
causing microbes – leaving behind resistant bacteria to reproduce uninhibited [63]. 
1.2.3. Extended-spectrum β-lactamases 
β-lactam drugs, such as penicillins and cephalosporins, are one of the most 
commonly prescribed groups of antibiotics for treating infections in humans. They 
work by inhibiting peptidoglycan biosynthesis of the bacterial cell wall, which 
consequently prevents bacterial growth and leads to cell death [64]. Third-
generation cephalosporins (3GCs) were developed in the 1970s and introduced into 
clinical use in the early 1980s. This was in response to the growing prevalence of 
TEM-1 and SHV-1 β-lactamases, enzymes capable of hydrolysing and inactivating 
the existing β-lactam drugs in E. coli and K. pneumoniae, [65]. These drugs 
signalled a step forward for treating infections caused by MDR Gram-negative 
bacteria [65]. However, shortly after their clinical introduction, separate incidents of 
plasmid-mediated resistance to 3GCs were discovered in Germany and France 
resulting from extended-spectrum β-lactamases (ESBLs) [66, 67]. These enzymes 
possessed hydrolysing activity against a broad range of β-lactams, including 3GCs 
[65]. 3GCs have been shown to select for ESBL-producing Enterobacteriaceae, and 
their use is considered to have played a prominent role in the development of β-
lactam resistance [68, 69]. ESBLs can be encoded on mobile plasmids making them 
easily transferrable between strains, and in the present day, multiple types of ESBL-
producing K. pneumoniae have been reported globally [65].  
1.2.4. Carbapenem-resistant K. pneumoniae 
Of the β-lactam drugs, carbapenems possess the greatest efficacy against Gram-
positive and Gram-negative bacteria and are used to treat serious MDR K. 
pneumoniae and E. coli infections [70]. However, the increased use of carbapenems 
resulted in the emergence of Klebsiella pneumoniae carbapenemase (KPC) 
enzymes. KPCs are β-lactamase enzymes which possess a broad substrate 
spectrum, capable of hydrolysing most antimicrobial drugs including penicillins, 
cephalosporins, β-lactamase inhibitors, and carbapenems. KPCs do not however 
confer resistance to the polymyxins and tigecycline [71-73]. Originally identified in 
the United States in 1996 as KPC-1 [74], KPC enzymes have now spread globally 
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among K. pneumoniae and other Gram-negative bacteria, typically plasmid-
mediated, with a range of KPC variants emerging [75].  
Alternative carbapenem resistance mechanisms have also evolved alongside KPCs, 
such as metallo-β-lactamases (MBLs). These are a diverse group of class B β-
lactamases capable of hydrolysing carbapenems [76]. Though MBLs were originally 
not considered a threat, attitudes towards them changed with the plasmid-mediated 
spread of IMP- and VIM-type MBLs in the 1990s [64]. More recently, a novel MBL 
was identified in 2008 when a carbapenem-resistant strain of K. pneumoniae was 
isolated in Sweden from a patient who acquired a UTI after travelling to New Delhi, 
India [77]. The isolate carried a highly transferrable gene, blaNDM-1, which produces 
New Delhi metallo-β-lactamase (NDM-1). NDM-1 is resistant to all antimicrobials 
except fluoroquinolones and colistin [77], and has since been reported worldwide 
[78-80]. The global dissemination of carbapenemases is a common trait among 
these enzymes, mainly associated with K. pneumoniae [81] and with a propensity for 
geographical preference e.g. KPC-Americas, NDM-Sub-continent [70, 81, 82]. As a 
result, the presence of carbapenmases represents a major obstacle to our ability to 
treat K. pneumoniae infections. 
1.2.5. Resistance to the last last-lines: the polymyxins  
The increasing prevalence of carbapenem-resistant K. pneumoniae and subsequent 
limitations of treatment has led to increased attention on the last-line polymyxin 
drugs, polymyxin B (PxB) and colistin (PxE) [80]. PxB and colistin are a class of 
cyclic polypeptide antimicrobials, discovered in 1947 [83] and clinically available in 
the 1950s [84], which have retained potency against Pseudomonas aeruginosa (P. 
aeruginosa), Acinetobacter and Enterobacter spp., as well as carbapenem-resistant 
K. pneumoniae [4]. The primary target of polymyxin activity in K. pneumoniae is the 
bacterial outer membrane (OM). Interactions between cationic polymyxins and the 
anionic lipopolysaccharide (LPS) of the OM destabilise OM stability and structure, 
resulting in increased permeability, cell leakage, and finally cell death [4] (Figure 4). 
Previously these antimicrobials had been set aside due to concerns surrounding 
their use and adverse effects, including nephrotoxicity and neurotoxicity [85, 86]. 
However, as other agents have become increasingly ineffective, the reliance on 
these drugs and their clinical use has grown [87, 88]. Indeed, a study by Neuner et 
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al. [89] looking at the effectiveness of various antimicrobials reported that 86% of 



















Despite this, K. pneumoniae isolates have recently emerged exhibiting resistance to 
all known antimicrobial classes, including the polymyxins. A plasmid-borne 
polymyxin resistance gene, mcr-1, was recently identified among swine in China 
[90]. This gene was originally identified in E. coli but capable of transference and 
maintenance in K. pneumoniae and P. aeruginosa. In vivo, mcr-1 expression 
Figure 4. Electron microscopy showing the results of P. aeruginosa after exposure to 
PxB (25 µg/ml) and colistin (250 µg/ml) for 30 min. A) untreated; B) treatment with PxB; 
C) treatment with colistin. After exposure to polymyxins, alterations and damage to the 
bacterial cell are clearly visible. Adapted from Falagas et al., 2005 [4]. 
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decreased the effect of colistin by altering lipid A structure of the LPS. Since its 
publication, further studies have reported the presence of mcr-1 in 
Enterobacteriaceae isolates from both humans and animals, indicating its global 
dissemination [91-93]. Colistin use in intensive farming, with China a notable 
example, has also seen the emergence of colistin-resistant isolates [94]. 
Carbapenem-resistant K. pneumoniae treated with polymyxin have also been shown 
to develop resistance in vivo [95-98]. Other mechanisms leading to colistin 
resistance are also emerging, and can be expected to increase with its growing use 
in treatment and its heavy use in farming [94]. A recent report by the CDC [21] 
detailed the case of an elderly patient in the USA who died in September 2016 as a 
result of septic shock. The patient was infected with a strain of carbapenem-resistant 
K. pneumoniae that displayed resistance to all available antimicrobials, including 
polymyxins. Despite the isolate’s resistance to colistin, it tested negative for the mcr-
1 gene, suggesting an alternative mechanism at play. 
1.2.6. Intrinsic mechanisms provide alternative paths to resistance 
Acquired resistance is clearly a factor in the development of resistance in K. 
pneumoniae, arising from spontaneous genetic mutations and the transfer of genetic 
material between bacteria via plasmids. However, K. pneumoniae already 
possesses a broad range of intrinsic mechanisms that enable it to resist and persist 
in harsh conditions. 
Intrinsic resistance is the innate ability of a bacteria to tolerate and survive in the 
face of antimicrobial pressure; resisting the bactericidal or bacteriostatic activity of 
antimicrobials due to inherent structural and functional processes [61]. This lack of 
sensitivity to an antimicrobial can result from numerous factors originating from the 
bacterium. Increased efflux pump activity can export toxic compounds from the cell. 
Decreased production of OM porins limits the influx of molecules into the bacterium. 
Additionally, alterations to external surfaces of bacteria prevent microbe recognition 
by antimicrobials, whilst intrinsically-produced inactivating enzymes are able to 
degrade and nullify antimicrobials [61]. It is the combination of these intrinsic 
mechanisms and extrinsic mechanisms which produce the most effective forms of 
resistance. The comprehensive resistance of K. pneumoniae to β-lactam drugs 
results from various factors, including increased efflux, altered porin activity, and β-
lactamase production [64, 70]. Resistance acquired via the transmission of genetic 
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material is an important factor in AMR. However, when combined with the range of 
mechanisms already inherently available to the bacterium, the severity of the AMR 
problem increases. 
Global transcription regulators play a major role in mediating intrinsic resistance, 
capable of activating and inhibiting the expression of a diverse range of 
physiologically important genes with roles in maintaining cellular homeostasis, 
biosynthesis, virulence and, significantly, resistance [61]. As a result, the importance 
of establishing the role of these transcription proteins is critical to the dual 
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1.3. RamA: transcription regulator and resistance mediator  
RamA belongs to a subfamily of AraC-type transcriptional proteins, which also 
includes MarA, SoxS, Rob and RarA [99-101]. They are unique among the AraC-
type protein family due to their ability to directly bind DNA as monomers [102] and 
pre-recruit RNA polymerase [103]. They subsequently regulate genes linked to a 
variety of cellular processes, including virulence and stress response [104], but of 
particular interest is their link to AMR. These proteins can regulate genes involved in 
controlling bacterial permeability, alterations to which have been established as a 
major factor in the development of resistance [105]. 
The first described MDR-associated AraC-type regulator was the MarA protein in E. 
coli, encoded within the chromosomal multiple-antibiotic-resistance (mar) locus 
[106]. MarA represents the prototype AraC-type resistance regulator, with 
homologues found among other Enterobacteriaceae [107]. MarA controls the 
expression of genes involved in bacterial permeability [108, 109], and there is 
considerable overlap between the genes regulated by MarA, and those controlled by 
SoxS, Rob and RamA [1, 109-113]. marA overexpression and its subsequent 
regulation of permeability genes generates a MDR phenotype, which is similarly 
conferred by overexpression of soxS, rob and ramA [109, 114]. The resistance 
phenotype of these regulators is typified by activation of efflux activity, such as 
upregulation of the AcrAB-TolC efflux pump [115, 116]; reduced influx, for example 
downregulation of the OM porin OmpF [117, 118]; and alterations to lipid A and LPS 
of the bacterial OM [1, 119]. 
AMR is a multifactorial process which can arise from single, separate events or 
result from a combination of mechanisms [61, 120]. Consequently, resistant 
Enterobacteriaceae isolates can demonstrate similar resistance phenotypes to a 
variety of antibiotics, but which develop from separate mechanisms. O’Regan et al. 
[121] reported that acrB overexpression, downregulated ompF, and LPS alterations 
resulting from overexpressed soxS, marA and ramA all contributed to resistance in 
different Salmonella enterica serovar Enteritidis (S. Enteritidis) isolates. This 
indicates a complex bacterial system where numerous compensatory resistance 
mechanisms are able to promote survival under harsh conditions. Furthermore, it is 
proposed that MarA, SoxS, Rob and RamA are essential components of early stage 
resistance development because they promote bacterial survival in the face of host 
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immunity or antimicrobial challenge. This provides sufficient time under selective 
pressure for the bacteria to develop or acquire further beneficial resistance 
mutations [1, 122].  
MarA, SoxS, Rob and RamA have all been shown to substantially contribute to the 
development of resistance to a broad range of antibiotics; however, their regulation 
of many resistance genes, such as the acrAB efflux pump or ompF porin, generally 
overlaps [1, 109, 110, 112, 123-125]. Therefore, what is unclear is the relative 
importance of each AraC-type regulator and what they contribute to AMR: is 
overlapping regulation a protective back-up mechanism in the event that one 
regulator is inactivated, or do specific regulators have more significant roles than 
others in AMR in a species- or gene-dependent manner? E. coli, for example, is able 
to resist antimicrobial challenge due to overexpression of marA, rob or soxS [109, 
124, 126]. However, RamA, which is not genomically encoded in E. coli [127], has 
been strongly linked to MDR in both K. pneumoniae and Salmonella spp. [125, 128-
130], and can activate expression of MarA-, SoxS-, and Rob-regulated resistance 
genes independently of these regulators [128, 131]. Furthermore, expression of K. 
pneumoniae ramA in E. coli is able to confer an identical MDR phenotype to that 
found in K. pneumoniae [101]. Contrastingly, it has been reported that inactivation of 
ramA does not increase antimicrobial susceptibility in S. Typhimurium [132]. 
However, the authors fail to take into account that the MDR phenotype is conferred 
by ramA overexpression, as opposed to normal ramA levels [1, 127], indicating that 
the proposed role of ramA from this study was not fully investigated. As a result, 
elucidating the significance of specific regulators in specific species is important to 
understanding resistance determinants and how best to counter them. Due to the 
emergence of K. pneumoniae as a MDR pathogen of increasing global importance, 
efforts to better understand the intrinsic mechanisms that contribute to bacterial 
AMR are essential. 
1.3.1. Regulation of ramA 
RamA is encoded by the ramA gene which, besides Klebsiella, is also found in other 
Enterobacteriaceae spp. including Enterobacter, Citrobacter and Salmonella [127, 
133, 134]. The ram locus is conserved in all of these organisms bar S. Typhimurium, 
which lacks the upstream romA gene, proposed to encode a MBL [1]. Under normal 
conditions, RamR, a TetR-type family regulator encoded by the ramR gene, 
represses expression of the romA-ramA genes. Basal ramA levels are maintained 
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due to the interaction of the small regulatory RNA sRamA5, a cleaved by-product of 
the romA transcript, with the repressor RamR, thus providing derepression to allow 
the basal levels of ramA transcription. Whilst RamR has a higher binding affinity, the 
competition of sRamA5 is sufficient to help maintain basal ramA expression [1]. 
Inactivating mutations to the ramR gene [135-137], and inhibitory ligand-mediated 
interactions with RamR [138, 139], result in increased ramA expression [138, 140], 
which subsequently confers a MDR phenotype [1, 127, 141, 142] (Figure 5). 
Inactivating ramR mutations leading to ramA overexpression have been reported as 
a result of tigecycline exposure [135, 143], which results in reduced susceptibility to 
this agent. Of interest, clinical isolates that pre-date the use of tigecycline also 
exhibit ramA overexpression, indicating the ability of other antibiotics to select for 
this change [134]. This implicates RamA as an important mechanism which K. 
pneumoniae can utilise to resist a range of antimicrobials. The development of 
tigecycline resistance is important because tigecycline is an antimicrobial of 
increasing interest for the treatment of MDR K. pneumoniae [144-146]. The role of 
RamA in conferring resistance to this agent is notable as it highlights a major role for 












Figure 5. Organisation of the ram locus in K. pneumoniae. A) Under normal conditions, 
expression of ramR results in repression of romA-ramA. The small regulatory RNA, sRamA5, 
interacts with RamR and competitively binds for the PI promoter, thereby maintaining basal 
levels of ramA expression. Inactivating mutations to ramR or repressive external signals allow 
unregulated expression of ramA. Adapted from de Majumdar et al, 2015. [1]. 
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1.3.2. The RamA regulon in K. pneumoniae and its role in resistance 
K. pneumoniae is a pathogen of growing importance in AMR due to the increasing 
prevalence of MDR strains worldwide. While several studies have reported the 
effects of RamA regulation in S. Typhimurium, until recently the scope of the RamA 
regulon in K. pneumoniae had not been addressed. In S. Typhimurium, RamA has 
been demonstrated to play an important role in bacterial resistance and survival 
after antimicrobial challenge [125, 140]. Studies have found that ramA gene 
disruption leads to decreased survival within macrophages [140]. Conversely, ramA 
overexpression leads to increased activation of MDR genes, including the efflux 
pump genes acrAB, acrEF, and tolC, and decreased expression of the porin gene 
ompF, resulting in decreased antimicrobial susceptibility [125, 140]. Overexpression 
also promotes immune evasion via reduced adhesion to, and improved survival 
within, macrophages [125, 140]. These findings indicate the importance of RamA 
regulation to the Salmonella AMR phenotype. 
The recent study by Majumdar et al. [1] determined the RamA regulon in K. 
pneumoniae Ecl8, revealing a total of 103 differentially expressed genes in the 
presence of increased ramA levels, with roles in a variety of important cellular 
processes. Importantly, when ramA is overexpressed, genes associated with 
bacterial permeability, such as efflux pump and porin genes, are most affected. 
Transcriptome and qPCR analyses of ramA overexpression showed overlaps with 
the regulons of MarA, SoxS, and Rob in different Enterobacteriaceae spp., with 
regards an upregulation of efflux pump gene acrAB [1, 108, 125, 140]. Additional 
OM-linked genes were shown to be upregulated: tolC, a component of the AcrAB 
efflux pump complex; the efflux-related operons oqxAB and yrbB-F; lpxL-2, encoding 
a lipid A biosynthesis lauroyl acyltransferase; and lpxO, another gene in the lipid A 
biosynthesis pathway encoding a dioxygenase [1]. The OM porin ompF, on the other 
hand, was downregulated. Furthermore, electrophoretic gel shift mobility assays 
(EMSAs) and transcription in vitro (IVT) assays confirmed that RamA is able to 
directly bind and activate the promoters of acrAB, yrbF, lpxL-2, and lpxO [1]. 
1.3.3. Significance of differentially modulated AcrAB, TolC and OmpF in AMR 
Efflux pumps play an important role in bacterial AMR; increasing the expulsion of 
toxic compounds from within the cell, preventing intracellular accumulation and 
negating lethal effects, and consequently promoting bacterial survival (Figure 6). 
Efflux pumps are effective due to the dynamic ways in which they confer resistance; 
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inherently resistant to a broad spectrum of antimicrobial classes or with high 
substrate specificity to specific drugs. Alternatively, resistance can be conferred by 
upregulated efflux as a result of gene mutation or mediated by global regulators 
[122]. In Enterobacteriaceae, numerous studies have demonstrated that 
overexpression of either acrAB or tolC genes, encoding the AcrAB-TolC efflux 
pump, often results from increased expression of the AraC-type regulators MarA, 
SoxS and  RamA [1, 99, 113, 126]. Consequently, this results in reduced 
susceptibility to a broad range of antimicrobials, as well as decreasing bacterial 
virulence [122, 147-149]. Previous studies have also established the importance of a 
functional AcrAB efflux pump in the resistance phenotype; in its absence, 
overexpression of MarA, RarA and RamA fail to confer resistance to a variety of 
antimicrobials [130, 150].  
Porins also play an important role in reducing antimicrobial susceptibility. These OM 
proteins, such as OmpF, participate in the diffusion of antimicrobials into the 
bacterial cell [105, 151]. Reducing the expression and activity of porins prevents the 
transport and build-up of antimicrobials and, combined with increased efflux activity, 
limits bacterial permeability sufficiently to reduce antimicrobial susceptibility [152-
155] (Figure 6). Expression of ompF is controlled by MarA, SoxS and RamA [1, 
156]. When these regulators are overexpressed, they activate expression of micF 
[157], an antisense RNA which subsequently decreases expression of ompF, 
reducing efflux and conferring reduced antimicrobial susceptibility [158-160]. 
Reduced bacterial permeability via increased efflux and reduced influx is an 
important intrinsic mechanism that K. pneumoniae can utilise in order to lower 
antimicrobial susceptibility. RamA is therefore a significant factor in conferring 
bacterial AMR due to its ability to upregulate and downregulate efflux and porin 
genes respectively [1]. However, RamA has also been shown to activate expression 
of the lipid A biosynthesis genes lpxL-2 and lpxO [1]. Lipid A is an important 
component of the Gram-negative OM, and RamA-mediated modifications to lipid A 
synthesis may be an important factor in preventing antimicrobial targeting and killing 
of bacteria. This indicates another potentially significant role that this intrinsic 
regulator has in conferring an AMR phenotype to K. pneumoniae. 
 
 


























Figure 6. Effect of RamA upregulation on bacterial permeability and antimicrobial 
susceptibility. A) Porins such as OmpF control import of molecules into the cell via diffusion, 
including antimicrobials, while efflux pumps are responsible for exporting foreign and harmful 
compounds; B) when the ramA repressor, RamR, is rendered inactive, ramA is upregulated. 
Subsequently, efflux activity increases and porin-mediated import decreases. These changes 
contribute to antimicrobial resistance. Adapted from Malinverni et al., 2009 [5]. 
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1.3.4. Lipid A of the Gram-negative outer membrane 
Controlling bacterial permeability is essential to the organism’s survival, and the 
Gram-negative bacterial OM plays a central role. It provides a vital protective barrier, 
acting as an obstacle in the path of macromolecules or hydrophobic antimicrobials 
due to its hydrophobic lipid bilayer composition [161]. Despite this, it succeeds in 
allowing uninterrupted import and export of materials essential for bacterial 
homeostasis, courtesy of interspersed OM porin proteins and efflux pumps. 
Lipopolysaccharide (LPS) is a major component of Gram-negative bacterial OMs 
and is essential for bacterial growth [105, 162-164]. It consists of three parts: a 
highly variable O-antigen and a core oligosaccharide region, which is anchored to 
the OM by lipid A, a phosphorylated disaccharide possessing hydrophobic fatty acid 
chains. LPS functions as an externally-facing protective barrier due to its 
hydrophobic nature, but also functions as an endotoxin, with lipid A the primary 
immunostimulant behind endotoxic activity [105].  
Lipid A forms the outermost layer of the Gram-negative OM, and subsequently has 
an important role in host-pathogen and host-drug interactions. Innate immunity is the 
host’s first line of defence against infection; its responsibility is to recognise 
pathogens and clear them quickly and effectively. Toll-like receptor 4 (TLR4) is a 
member of the TLR family of pattern-recognition receptors (PRRs) which 
differentiate between the host and threats by recognising pathogen-associated 
molecular patterns (PAMPs). The lipid A of LPS is one such PAMP to which TLR4 
has specificity [165-169]. TLR4 recognition of LPS induces a signalling cascade 
which stimulates the production of pro-inflammatory cytokines [165], induces 
macrophages to produce inflammation mediators such as TNF-α and IL-1β [170, 
171], and is also able to activate co-stimulatory molecules that trigger adaptive 
immunity [172, 173]. Whilst these responses are fundamental to innate immunity 
and beneficial to clearing infection from the host, when overproduced, for example 
during sepsis, the lipid A stimuli elicit an overwhelming inflammation response which 
causes harmful damage to the host, potentially resulting in septic shock [174, 175].  
Lipid A and the LPS core region carry several anionic groups, resulting in a net 
negative charge which favours cation binding. This allows for strong lateral 
interactions between neighbouring anionic LPS molecules and divalent cations in 
the OM, presenting an effective barrier projecting from the OM surface [161]. 
However, while the anionic nature of LPS is fundamental to its ability to form a 
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hydrophobic barrier, it also makes LPS a prime recognition and binding candidate 
for cationic antimicrobial peptides (CAMPs), including polymyxin drugs and CAMPs 
generated by the host immune response [105].  
The polymyxins PxB and colistin are last-line CAMPs whose therapeutic use in 
MDR-K. pneumoniae infections has seen a resurgence alongside the rise of strains 
resistant to all other available agents [4, 80]. The mechanism behind polymyxin 
bactericidal activity is two-fold: initially, due to a higher binding affinity, the cationic 
polymyxins competitively displace the divalent cations of the OM to bind anionic lipid 
A, destabilising and permeabilising the OM; this in turn allows access to the bacterial 
inner membrane (IM), where subsequent permeabilisation and cytoplasmic leakage 
lead to cell death [105, 161, 176]. When used singularly, polymyxins possess 
effective bactericidal activity [176, 177], though resistance to monotherapy has been 
shown to quickly develop [178, 179]. However, combination therapy with additional 
drugs holds great promise. Because even low polymyxin concentrations are 
sufficient to permeabilise the OM, polymyxin is able to facilitate the passage of 
hydrophobic antimicrobials to which the OM would otherwise be resistant, 
dramatically increasing sensitivity [161, 180-182].  
1.3.5. The role of lipid A modifications in contributing to polymyxin 
resistance and promoting bacterial survival 
An essential step in polymyxin-mediated bacterial killing is the electrostatic 
interaction between the CAMP and the anionic lipid A of LPS. As a result, Gram-
negative species have developed various mechanisms to counter the effects of 
CAMPs, many of which rely on modifications to lipid A [176] (Table 1). Canonical 
lipid A is expressed by the E. coli K12 strain, and lipid A biosynthesis genes are 
conserved amongst Gram-negative bacteria [183]. However, lipid A structure is 
heterogeneous, characterised by varying fatty acid chains, different chemical 
moieties, and diverse acylation and phosphate patterns, all of which can contribute 
to resistance and persistence [183, 184]. The most common lipid A modifications are 
achieved through the addition of 4-amino-4-deoxy-L-arabinose (L-Ara4N) and 
phosphoethanolamine (PEtN) [185-190]. These lipid A modifications have the effect 
of lowering the net negative charge of LPS [176], potentially decreasing the natural 
repulsion between neighbouring anionic LPS molecules and producing a more 
closely packed layer of LPS [105]. As a result of the decreased negative charge of 
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LPS, initial polymyxin-pathogen interactions are limited, thereby reducing polymyxin-
mediated permeabilisation of the OM and preventing cell death [176, 177].  
In Klebsiella spp., lipid A modifications are controlled by the auto-regulating PhoP-
PhoQ (PhoPQ) two component regulatory system [177]. This two-component 
system (TCS) is also found in other Gram-negative bacteria including Salmonella 
spp., E. coli, and P. aeruginosa. TCSs allow bacteria to regulate gene expression 
and mediate adaptive changes in response to environmental stimuli. The 
membrane-localised PhoQ sensor protein responds to environmental low divalent 
cation concentrations, such as Mg2+ starvation or the presence of CAMPs, by auto-
phosphorylating [191, 192]. It then activates the cytosolic PhoP DNA-binding 
response regulator via a transphosphorylation reaction which leads to activation or 
repression of target genes [193-195]. PhoPQ also regulates the PmrA-PmrB 
(PmrAB) two-component system, creating a signal cascade which in turn modulates 
expression of genes involved in lipid A modification. PhoPQ and PmrAB-regulated 
genes involved in lipid A modifications include pmrC, responsible for PEtN synthesis 
[196]. Also regulated are pmrE and pmrH, which encode enzymes responsible for 
synthesising and attaching L-Ara4N to lipid A, neutralising the negative charge of 
LPS and generating a phenotype associated with colistin resistance [196-199]. 
PmrAB is also able to regulate lipid A modifying genes independently of PhoPQ, 
where the PmrB sensor autophosphorylates in response to low pH or environmental 
levels of Fe3+ [188, 200], before activating the response regulator PmrA [201]. 
Mutations in PhoPQ and PmrAB resulting in their constitutive expression lead to 
resistance to polymyxins as well as a range of structurally distinct CAMPs [177, 
202]. Unsurprisingly, inactivating mutations have the opposite effect whereby 
susceptibility to CAMPs is dramatically increased [202-204]. In particular, 
constitutive activation of PhoP as a result of phoQ mutation results in reduced 
susceptibility to polymyxins and CAMPs [198, 203, 204], whilst when PhoP is 
inactivated, mutants become hyper-sensitive [194, 202]. PhoPQ is also negatively 
regulated by the mgrB gene, inactivating mutations of which give rise to colistin 
resistance in MDR K. pneumoniae [205, 206]. 
An additional way in which lipid A modifications are proposed to contribute to 
bacterial survival is via evasion of innate immunity. These modifications may result 
in the failure of PRRs of the immune response to recognise bacterial lipid A and 
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Table 1. Polymyxin resistance mechanisms of Gram-negative bacteria. 
detect the presence of the bacterium. TLR4 has difficulty recognising PhoPQ-
regulated lipid A [207] with PhoPQ-mediated lipid A deacylation and palmitoylation 
implicated [208]. This essentially hides the pathogen from the host’s immune 
system, and in K. pneumoniae has been shown to limit activation of inflammatory 
responses [183]. As a result, the role of these regulatory TCSs and lipid A 
modifications are crucial to immune evasion and to the development of CAMP 
resistance in various Gram-negative bacteria, including K. pneumoniae. 
 
 
Bacterium Examples of resistance mechanisms 
P. aeruginosa PmrA/PmrB-mediated lipid A modifications with l-Ara4N 
S. Typhimurium 
PmrA/PmrB-mediated lipid A modification with both l-Ara4N and 
PEtN 
The gene mig-14 is required for resistance but does not involve LPS 
modification  
E. coli 
PmrA/PmrB-mediated lipid A modification with both l-Ara4N and 
PEtN 
K. pneumoniae Increased production of capsule polysaccharide.  
Vibrio cholerae Presence of OM protein OmpU regulated by ToxR  
 
Table 1. Many resistance mechanisms that Gram-negative bacteria have developed in 
response to CAMPs involve modifications to lipid A of the LPS. This affects overall net 
charge, thereby impacting on and limiting the initial electrostatic interaction between CAMPs 
and the bacterial OM. Adapted from Zavascki et al., 2007 [176].  
 
1.3.6. LpxO modifies lipid A, contributing to AMR 
The lpxO gene has orthologues in various Gram-negative bacteria, including 
Salmonella and Klebsiella spp.. It encodes LpxO, an IM-localised dioxygenase with 
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an active site predicted to face into the cytoplasm [191]. Conditional on bacterial 
growth in O2, LpxO is involved in the biosynthesis of the 2-hydroxymyristate 
modifications of specific lipid A acyl chains [184, 209]. This moiety is proposed to 
enhance hydrogen bonding between lipid As, stabilising the OM and increasing its 
impermeability [191]. Expression of Salmonella lpxO in E. coli K-12, which does not 
naturally possess the gene, introduces the ability to modify lipid A with 2-
hydroxymyristate in an O2-dependent manner [209]. In S. Typhimurium, lpxO 
inactivation results in the abolition of 2-hydroxymyristate-modified lipid A [191].  
In S. Typhimurium, lpxO expression is in part regulated by PhoPQ [207, 209, 210]. 
PhoPQ is essential for bacterial resistance to CAMPs and can also be induced by 
CAMPs, leading to PhoPQ-mediated activation of virulence and resistance genes, 
including lipid A modifiers [211, 212]. Llobet et al. [211] reported that pre-treatment 
of K. pneumoniae with PxB produced lipid A with modifications that contributed to 
cross-resistance to host immune CAMPs. Among these lipid A modifications, 
species were recovered that possessed hydroxymyristate modifications which 
correspond to the activity of LpxO in S. Typhimurium [211]. This indicated a possible 
K. pneumoniae LpxO orthologue and a potential role for this enzyme in CAMP-
induced resistance [211]. The presence and activity of K. pneumoniae LpxO was 
later confirmed in a subsequent study by Llobet et al. [183]. They reported that K. 
pneumoniae is able to modify its lipid A in a tissue-dependent manner. Lipid A 
recovered from the lungs of a K. pneumoniae murine infection model demonstrated 
a lipid A moiety consistent with the PhoPQ-regulated, LpxO-dependent 2-
hydroxymyristate modification [183]. This lipid A modification reduced susceptibility 
to CAMPs and inhibited activation of inflammation responses. The authors suggest 
that the LpxO-mediated, tissue-dependent lipid A modification recovered from the 
lung was due to induction by CAMPs, likely present in the environment at sub-
inhibitory concentrations. This is consistent with their findings that the same in vivo 
lipid A pattern was inducible by colistin, while existing colistin-resistant isolates 
already expressed it [183]. This indicates the ability of K. pneumoniae to modulate 
gene expression to promote survival, and the potential importance of LpxO in 
mediating immune evasion and resistance to CAMPs. 
It has been reported in S. Typhimurium that lpxO is able to remain active in the 
absence of PhoPQ regulation [213-215]. Recently, Majumdar et al. [1] established 
the role of RamA as a regulator of lpxO in K. pneumoniae. Overexpression of ramA 
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led to increased expression of lpxO apparently independent of PhoPQ, as no 
concurrent increase in phoP expression was observed. They also demonstrated that 
ramA overexpression in K. pneumoniae leads to reduced susceptibility to PxB, 
colistin, and the human CAMP LL-37 [1]. Overexpression of ramA upregulates efflux 
pump genes acrAB and tolC, and downregulates the porin gene ompF [1], the 
effects of which are associated with conferring increased resistance to antimicrobials 
[122, 148, 152]. In K. pneumoniae, RamA-mediated decreased antimicrobial 
susceptibility to most drugs is reliant on the presence of a functional AcrAB efflux 
pump [1]. AcrAB in K. pneumoniae has also been shown to have a possible role in 
virulence and CAMP resistance; where acrAB knockout mutants demonstrate a 
reduced ability to cause pneumonia in mice, and increased susceptibility to CAMPs 
from the human lung [216]. However, resistance to polymyxins and host immune 
peptides is often attributed to lipid A modifications that affect the ability of CAMPs to 
bind and permeabilise the bacterial OM [176, 177]. In addition, in K. pneumoniae 
ramA overexpression protects the bacterium from macrophage uptake, consistent 
with previous reports whereby modified lipid A contributes to immune evasion [183, 
207, 208]. As a result, the contributions of the various resistance associated genes – 
lpxO, acrAB, tolC, and ompF – to the RamA-mediated AMR phenotype are 
unknown. Regulation of bacterial permeability or lipid A modifications may play a 
role in individually reducing antimicrobial susceptibility, or may work in concert to 
promote higher levels of resistance (Figure 6). 
There is a scarcity of literature concerning lpxO, relative to the well-characterised 
efflux pump and porin genes. The role of LpxO in conferring lipid A-mediated CAMP 
resistance and promoting immune evasion in K. pneumoniae still needs exploration, 
and the specific factors behind its regulation are unclear. MDR K. pneumoniae is on 
the rise, and resistance to even last-line polymyxin drugs is beginning to emerge. 
Understanding how polymyxin resistance develops is crucial to efforts to combat the 
increasing threat of this global pathogen. Defining the regulation of lpxO and its 
contribution to the AMR phenotype in K. pneumoniae is an important step in 
elucidating the mechanisms that this bacterium employs to resist and persist in the 
face of antimicrobial challenge. 
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2.  Hypothesis 
 
It is established that K. pneumoniae RamA contributes to changes in antimicrobial 
susceptibility to a broad range of agents through the perturbation of microbial 
permeability, via altered efflux and influx. Increased ramA expression results in 
decreased susceptibility to the last line polymyxin antimicrobials, PxB and colistin 
[1]. It has also been reported that the lpxO gene is upregulated in response to 
increased ramA expression [1].  The function of LpxO is to modify bacterial lipid A in 
a way that stabilises and impermeabilises the bacterial OM [191], and lpxO 
expression confers a similar phenotype of reduced CAMP susceptibility and 
increased virulence  to that observed with ramA overexpression in K. pneumoniae 
[1, 183, 211]. As a result, how RamA-mediated changes to microbial permeability 
and modifications to lipid A contribute to and control polymyxin susceptibility is still 
uncertain. Given that the target of CAMPs and polymyxins is the bacterial OM, we 
hypothesise that RamA-mediated regulation of lipid A is a key factor in conferring 
resistance to polymyxins and CAMPs. 
The relevance of RamA regulation is reflected in the potential implications these 
changes will have on both antimicrobial resistance and virulence. The recent and 
rapid emergence of colistin-resistant K. pneumoniae isolates has made it critical to 
understand the basis of transmission and dissemination of these isolates. Given the 
increasing reliance on colistin to treat MDR K. pneumoniae infections, it is essential 












3.  Aims 
 
1. Characterise the impact of lpxO inactivation on susceptibility to the last-line 
polymyxins, PxB and colistin and its regulation by RamA. LpxO-mediated lipid 
A modifications have been reported to be important for resistance to CAMPs and 
colistin in K. pneumoniae [183, 206], whilst ramA overexpression is linked to a 
similar phenotype, as well as to increased expression of lpxO [1]. We planned to 
generate lpxO knockout mutants in K. pneumoniae w/t and ramA overexpressing 
strains. This would allow us to assess if loss of LpxO-mediated lipid A modifications 
affects the RamA-mediated MDR phenotype, and thereby examine whether RamA 
regulation of lpxO is important for polymyxin resistance. 
2. Determine the role of PhoPQ in the RamA-mediated AMR phenotype and 
regulation of lpxO. RamA and PhoPQ have both been linked to the regulation of 
lpxO in K. pneumoniae [1, 183, 211]. We sought to determine whether PhoPQ 
contributes to the AMR phenotype attributed to ramA overexpression [1] through 
regulation of lpxO. We aimed to achieve this by generating phoPQ knockout mutants 
in w/t and ramA overexpressing backgrounds and comparing polymyxin 
susceptibility to corresponding lpxO knockouts.  
3. Define the contribution of lpxO, ramA and phoPQ overexpression to 
polymyxin and tigecycline resistance. Overexpression of ramA is associated with 
tigecycline and polymyxin resistance through regulation of bacterial permeability 
genes [1, 125, 140], whilst phoPQ is associated with resistance to CAMPs and 
polymyxins via regulation of lipid A modifying enzymes [177, 183, 196-199, 211]. 
LpxO-mediated lipid A modifications have been shown to be important for CAMP 
and colistin resistance, and lpxO is regulated by RamA and PhoPQ [1, 183, 211]. 
Therefore we aimed to determine and compare the effects of lpxO, ramA and 
phoPQ overexpression in K. pneumoniae on susceptibility to tigecycline, PxB and 
colistin. We generated plasmid constructs overexpressing these genes and 
introduced them into w/t and ramA overexpressing strains, comparing susceptibility 
phenotypes with K. pneumoniae strains possessing knockouts of RamA-regulated 
permeability genes. 
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4.1. Bacterial growth conditions 
Generally, bacteria were grown from frozen -80°C stocks on Luria-Bertani (LB) agar 
(1.5% bacteriological agar, 1% tryptone, 1% NaCl, and 0.7% yeast extract) at 37°C. 
The resultant single colonies were used to inoculate 5 ml of LB broth (Formedium 
LB broth Lennox) with/without antibiotics for selection and shaken at 37°C or 30C 
overnight. 
4.2. Cell lysate DNA (PCR template) 
4.2.1. Broth culture 
Bacteria were inoculated in LB broth and left to shake overnight, with antibiotics and 
temperature dependent on the strain. Overnight culture was decanted into a micro-
centrifuge tube and centrifuged for 3 min at maximum (max) speed. Supernatant 
(SN) was removed and the pellet re-suspended in sterile distilled H2O (sdH2O); this 
was again centrifuged for 3 min at max speed, SN removed, and the pellet re-
suspended in sdH2O. The sample was placed in a heating block at 95°C for 10 min, 
then immediately chilled on ice for 5 min. The sample was centrifuged for 3 min at 
max speed, with the resulting DNA-containing SN removed for immediate use or 
storage at -20°C. 
4.2.2. Agar plate colony 
A single colony was picked from an agar plate and re-suspended in 100 μl sdH2O. 
The sample was then heated at 95°C for 10 min, before being chilled on ice for 10 
min. After centrifugation for 3 min at max speed, the DNA-containing SN was 
removed and stored at -20°C. 
4.3. Polymerase Chain Reaction (PCR) 
For PCR screening, Bioline MyTaqTM DNA Polymerase was used as per the 
manufacturer’s protocol. For amplification of DNA to be subsequently used in 
downstream reactions, NEB Q5® High-Fidelity Polymerase was used. 
4.4. PCR and gel purification 
PCR purification was performed using the ThermoFisher GeneJET PCR Purification 
Kit, as per the manufacturer’s protocol. For gel purifications, the PCR purification 
protocol was followed, with the additional step of melting a 1:1 mixture of excised 
DNA-containing gel and binding buffer at 55°C for 10 min, prior to using the spin 
column. 
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4.5. Genomic DNA purification 
Genomic DNA purification was performed using the Promega Wizard Genomic DNA 
Purification Kit, as per the manufacturer’s protocol. 
4.6. Gram-negative plasmid extraction 
Bacterial cultures grown overnight were decanted into micro-centrifuge tubes which 
were then centrifuged for 3 min at max speed, with the SN discarded. The bacterial 
pellet was re-suspended in 200 μl of Solution 1 (50 mM Tris-Cl pH 8.0, 10 mM 
EDTA, RNAse A 0.1 g/L) by vortexing, followed by the addition of 200 μl Solution 2 
(200 mM NaOH, 1% SDS (sodium dodecyl sulfate)) with gentle mixing by inversion 
in order to lyse the cells. Two hundred microlitres of Solution 3 pH 5.5 (3 M 
potassium, 5 M acetate) was added, which created a precipitate of cellular 
components and DNA. The samples were chilled on ice for 5 min, and then 
centrifuged for 10 min at max speed. The resulting DNA-containing SN was 
transferred to micro-centrifuge tubes containing 450 μl isopropanol and mixed 
thoroughly by inversion, after which they were left to stand for 5 min and then 
centrifuged for 10 min at max speed. SN was discarded leaving only the DNA pellet, 
which was gently washed with 70% ethanol. The ethanol was removed and the 
pellet air-dried for 10-15 min to evaporate the ethanol. The DNA pellet was finally re-
suspended in 50 μl dH2O and stored at -20°C. 
4.7. DNA ligation reactions 
Ligation reactions used a set formula, detailed below, to calculate the amount of 
insert required for the concentration of vector used. Ligation reactions were 
incubated overnight at 4°C, before transformation into calcium-competent cells the 
following day. 






4.8. Calcium-competent cells (CCs) 
Fifty millilitres of LB broth was inoculated with overnight culture with/without 
antibiotics for selection, which was then grown to O.D.600 0.6. The culture was 
centrifuged for 15 min at 4°C, 4,000 rpm, and the SN discarded. The pellet was re-
suspended in 50 ml of ice-cold 0.1 M CaCl2, re-centrifuged, and SN discarded. This 
was repeated twice more, with 25 ml and 5 ml of ice-cold 0.1 M CaCl2. Finally, the 
suspension was centrifuged for 15 min at 4°C, 4,000 rpm, with SN discarded and the 
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pellet re-suspended in 1 ml of ice-cold 0.1 M CaCl2 and 110 μl of 90% glycerol. CCs 
were stored at -80°C and validated before use. Validation involved inoculating agar 
plates containing antibiotics to which CCs should be sensitive, to confirm that CCs 
were not contaminated. 
4.9. Heat-Shock transformation 
Ligation reactions were mixed with 100 μl of CC-DH10β cells and incubated on ice. 
After 30 min, the reaction was placed in a 42°C water bath for 45 sec, before being 
returned immediately to ice for 1 min. One millilitre LB broth was added and the 
reaction incubated for 1.5 hours at 37°C. After incubation, the reaction was spun 
down, SN discarded and the pellet re-suspended in 100 μl LB broth. Ten and ninety 
microlitres were plated on separate LB agar (with/without antibiotics for selection) 
and grown overnight at 37°C. 
4.10. Electro-competent cells (ECs) 
Overnight culture was used to inoculate 50 ml LB broth 1:100, with/without 
antibiotics for selection, and grown to O.D.600 0.6. The culture was centrifuged for 15 
min at 4°C, 4,000 rpm, and the SN discarded. The pellet was re-suspended in 50 ml 
ice-cold 10% glycerol, re-centrifuged, and the SN discarded. This was repeated 
twice more, before a final re-suspension of the pellet in 500 μl ice-cold 10% glycerol. 
Washing steps are intended to remove salts from cells in order to protect them from 
electroporation; addition of glycerol is for protection during freezing. Forty microlitre 
volumes of this suspension were aliquoted into micro-centrifuge tubes for immediate 
use or storage at -80°C, with one sample used for validation (see CC cells).  
4.11. Electroporation transformation 
Electroporation cuvettes were chilled on ice for 15 min before EC cells were added. 
For each sample of cells to be electroporated with plasmid, a control sample was 
also set up. These controls were treated in the same way, minus the addition of 
plasmid. The amount of plasmid used varied depending on its purpose; 250 – 1000 
ng was added to cells which were then mixed. Each sample was then pulsed with 
1800 V, following which 1 ml of LB broth was immediately added and mixed. The 
samples were shaken for 1 hour, after which they were centrifuged for 3 min at max 
speed, SN discarded, and re-suspended in 100 μl LB broth. Ten and ninety 
microlitres of each sample were aliquoted onto separate LB agar plates, with the 
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necessary antibiotic selection. These plates were left to grow for 24 to 48 hours at 
either 30 or 37C. 
4.12. Gene exchange protocol 
The exchange protocol was performed as previously described by Merlin et al. [217]. 
The method requires the replacement of the target gene with a FRT (Flp recognition 
target)-flanked cassette containing the kanamycin resistance (KmR)-encoding aph 
gene. This cassette resides within a temperature-sensitive pTOF plasmid which also 
possesses a chloramphenicol resistance (CmR)-encoding gene. The process 
comprises three steps: integration of the Km cassette into the bacteria by 
homologous recombination; purification of the bacterial population, where the Km 
cassette is integrated into the bacterial chromosome and transformants cured of the 
pTOF plasmid; and generation of the mutant strains, where colonies displaying 
appropriate phenotypic and genotypic characteristics are frozen and stored for future 
work. The process provides simple selection for correct, gene-deleted transformants 
via acquisition of KmR and loss of CmR. Furthermore, due to the FRT sites flanking 
the cassette, the cassette can be excised by a Flp recombinase-producing plasmid 
at a later stage. 
The Km cassette-bearing pTOF plasmid was electroporated (250 ng) into the 
appropriate strain for target gene replacement and left to grow overnight at 30°C on 
LB agar/Km plates. Single colonies were picked and grown in LB broth/Km overnight 
in a 30°C shaker. The culture was serially diluted 10-fold, spread on LB agar/Km 
and incubated at 30°C and 42°C. The higher temperature of 42°C prevents the 
plasmid from autonomously replicating; the large single colonies that result from 
these conditions indicate that the cassette has been forced to integrate with the 
chromosome and are therefore viable for continuing the protocol. At 30°C, the 
control temperature permissive for plasmid replication, no large colonies should be 
present and colonies will be indistinguishable from each other. Large single colonies 
from 42°C plates were picked and purified by streaking on LB agar/Km plates and 
incubating overnight at 42°C. This step was repeated to ensure transformants were 
cured of plasmid. Following the second 42°C incubation, single colonies from each 
streaking were pooled in LB broth/Km and shaken overnight at 30°C. LB broth was 
then inoculated 1:1000 with overnight culture and shaken overnight at 30°C, to 
relieve selective pressure and to allow full integration of the cassette. After repeating 
this step, 10-fold dilutions of suspension were prepared and spread on LB agar/Km 
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plates for overnight growth at 30°C. Resulting single colonies were patched onto LB 
agar plates containing antibiotics to which the bacteria should be sensitive (CmS) 
and resistant (KmR), and incubated overnight at 30°C. Chloramphenicol-sensitive 
(CmS) and KmR clones indicate that the plasmid has been removed from the bacteria 
and that a successful cassette replacement has taken place. CmS and KmR colonies 
were tested by PCR to confirm presence of the Km cassette in place of the target 
gene. Primer combinations which amplify the region where cassette meets 
chromosome were used: Next/Cext primers directed towards the cassette; and 









4.13. Km cassette removal with pCP20 
The temperature-sensitive plasmid pCP20 encodes Cm and ampicillin (Amp) 
resistance genes, and also possesses the FLP recombinase gene, flippase (Flp). 
pCP20 is used to remove the Km cassette from  between FRT sites by site-specific 
recombination [218].  
Km cassette-containing ECs were electroporated with 1 μg of plasmid pCP20. LB 
broth was added and cells shaken at 30°C. The suspension was centrifuged, SN 
discarded and the bacterial pellet re-suspended in LB broth. The sample was then 
incubated overnight on LB agar/Cm plates at 30°C for cassette excision. As 
Figure 7. PCR verification of gene replacement. Primer combinations featuring inward 
facing Next/Cext primers amplifying cassette flanking regions, and outward facing 
Km1/Km2 within the cassette, were used to confirm the presence of the cassette. 
P a g e  | 45 
 
  
previously described, 30°C is sufficient for basal flp expression to mediate FRT 
recombination [218]. Resulting single colonies were re-streaked on LB agar/Cm 
plates and incubated overnight at 30°C. Single colonies were then patched on LB 
agar/Km and LB agar/Cm plates and incubated overnight at 30°C to screen for loss 
of the Km cassette and consequently loss of KmR. KmS and CmR clones were then 
streaked on LB agar plates and incubated overnight at 42°C to cure transformants of 
pCP20. Single colonies were patched on LB agar and LB agar/Cm plates and 
incubated overnight at 30°C to screen for loss of CmR, and therefore loss of pCP20. 
CmS clones were tested by PCR to confirm removal of the Km cassette [217]. 
4.14. Relative Survival Assay (RSA) 
The RSA was performed as described previously [219], with minor modifications. 
Overnight culture was used to inoculate LB broth, which was grown to O.D.600 0.6. 
One millilitre of O.D.600 0.6 culture was centrifuged for 2 min at 12,000 rpm, and the 
SN discarded. The bacterial pellet was re-suspended in 1 ml 10 mM PBS (pH 6.5), 
centrifuged for 2 min at 12,000 rpm, and the SN discarded. This step was repeated 
three times, before final re-suspension in 1 ml 10 mM PBS (pH 6.5). A suspension 
was created of 105 CFU/ml in 10 mM PBS (pH 6.5), 1 % tryptone soy broth (TSB), 
and 100 mM NaCl. Five microlitre aliquots of this suspension was treated with 
different concentrations of PxB or colistin (0.033, 0.064, 0.096, 0.128, 0.192, 0.256 
μg/ml), to a final volume of 30 μl made up with 10 mM PBS (pH 6.5). All samples 
were incubated statically for 1 hour at 37°C. Following incubation, samples were 
diluted serially in 10 mM PBS (pH 6.5) and 50 μl of the final dilution was plated on 
each half of an LB agar plate, in duplicate. After overnight incubation at 37°C, 
colonies were counted, CFU/ml determined, and the survival percentage of exposed 
bacteria calculated with respect to untreated samples.  
4.15. Minimum Inhibition Concentration (MIC) assay 
MICs were performed using the doubling agar dilution method as described 
previously [220, 221]. LB agar plates were made up with varying concentrations of 
antibiotics (Table 5). Overnight cultures were diluted to 10-4 in 1x PBS, then 400 μl 
of each culture added to a 37 well inoculation mould. The mould was placed onto a 
Denley Multipoint Inoculator, with the inoculation pins sterilised in 100% ethanol 
prior to use. Agar plates were inoculated, left briefly to dry and then incubated 
overnight at 37°C. In the morning, plates were scored and the MIC values 
determined where growth was no longer visible. 
P a g e  | 46 
 
  
Table 2. Strains used in this study 
4.16. Data analysis 















































Table 4. Plasmid list 
Table 3. Primer list 


























Table 5. Antibiotic concentrations used 
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5.   Results 
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5.1.  Construction and validation of mutants in K. pneumoniae 
The aims of this project were to characterise the contribution of the RamA 
transcription regulator and the PhoPQ two-component system in the regulation of 
lpxO in K. pneumoniae. RamA and PhoPQ are associated with mediating a 
resistance phenotype to cationic antimicrobials via their regulation of bacterial 
permeability and lipid A-modifying genes respectively [1, 177, 183, 196-199, 211]. 
Additionally, both have been linked to lpxO regulation in previous studies in K. 
pneumoniae [1, 183, 211]. We sought to determine the role of lpxO in generating a 
resistance phenotype to the last-line cationic polymyxins, PxB and colistin. Previous 
reports in K. pneumoniae have demonstrated that PhoPQ-regulated lpxO 
overexpression mediates CAMP resistance and immune evasion [183, 211], with a 
similar phenotype observed in strains overexpressing ramA [1].  
To achieve these goals, we needed to generate lpxO and phoPQ knockout mutants 
in K. pneumoniae wild-type (w/t) Ecl8 and ramA-overexpressing Ecl8ΔramR 
backgrounds. The removal of lpxO in these backgrounds would allow us to a) 
establish whether the presence of lpxO is necessary for PxB and colistin 
susceptibility; and b) determine if a functional lpxO gene in the presence of ramA 
overexpression is necessary to mediate polymyxin and CAMP susceptibility. The 
generation of ΔphoPQ mutants in w/t and ramA-overexpressing strains would allow 
us to confirm if RamA-mediated regulation of the lpxO gene is co-dependent on a 
functional phoPQ locus.  
5.1.1. Validation of previously generated ΔlpxO mutants 
The original plan for this project did not require construction of new ΔlpxO mutants 
due to the presence of existing ΔlpxO mutants in Ecl8 and Ecl8ΔramR backgrounds; 
Ecl8<lpxO>Km and Ecl8ΔramR<lpxO>Km respectively. These were generated 
previously using a gene exchange protocol, whereby the target lpxO gene is 
replaced with a kanamycin (Km) resistance cassette. Prior to performing 
characterisation experiments to assess the impact of gene loss on antimicrobial 
susceptibility, these mutants first had to be validated by PCR to confirm the loss of 
the lpxO gene. PCR screening using lpxO qPCR primers (Table 3) instead 
confirmed the presence of the gene on two separate occasions, indicating that the 
previously generated Ecl8<lpxO>Km and Ecl8ΔramR<lpxO>Km mutants had in fact 
been unsuccessful (Figure 8). As a result, this required the construction of new 
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Figure 8. PCR validation of existing ΔlpxO mutants. On two separate occasions (shown in 
both panels), agarose gel electrophoresis of PCR products showed a 200 base pair (bp) band 
for all strains tested. This was equivalent to the expected fragment size for the lpxO qPCR 
primers used, indicating presence of the gene in all strains including putative mutants. 
 
including putative ΔlpxO mutants.  

















5.1.2. Genetic mutant construction methodology 
In light of the confirmation that existing lpxO mutants were not as they appeared, we 
generated new lpxO and phoPQ knockout mutants. The exchange protocol required 
a pre-existing pTOF plasmid, for an accurate description of which refer to Merlin et 
al., 2002 [217]. The pTOF plasmid carries a gene-specific cassette containing Km 
and Cm resistance genes, with lpxO/phoPQ gene flanks (lpxONoCo/phoPQNoCo) 
cloned into it. The recombinant construct would then be introduced into either K. 
pneumoniae w/t Ecl8 or Ecl8ΔramR by electroporation. Following a series of 
experimental steps involving incubations at 30°C or 42°C, the lpxO gene is replaced 
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by the Km cassette via a process of homologous recombination. The exchange 
protocol consisted of three key steps: integration of the cassette into the 
chromosome; purification of clones with the correct phenotype; and successful 
mutant generation, confirmed by a kanamycin resistant (KmR) and chloramphenicol 
sensitive (CmS) phenotype and PCR screening for the presence of the cassette.  
Electro-competent cells derived from Ecl8 and Ecl8ΔramR were transformed with 
the temperature-sensitive pTOF plasmid containing the gene-specific (either lpxO or 
phoPQ), FRT-flanked Km cassette. Transformed cells were then incubated on LB 
agar/Km at 30°C overnight. The Km cassette allows growth and selection of 
plasmid-possessing bacteria in the presence of Km. Overnight incubation at 30°C 
keeps the temperature-sensitive plasmid viable, whilst homologous recombination 
takes place between the integrating Km cassette and the chromosomal region it 
specifies for. A second overnight incubation in LB broth/Km at 30°C was followed by 
growth overnight at 42°C on LB agar/Km. Km exposure maintains selection for the 
Km cassette, and the elevated temperature at 42°C prevents the plasmid from 
autonomously replicating, ensuring only cassette-chromosome integrants survive. 
Large single colonies, representing the desired recombinants, were picked and 
purified by re-streaking on LB agar/Km for overnight growth at 42°C. Single colonies 
were then pooled and incubated overnight at 30°C in LB broth to temporarily relieve 
selective pressure and allow recombination to complete. The final steps involved re-
introduction of Km selection via serial dilution of overnight culture onto LB agar/Km 
and overnight incubation at 30°C. Single colonies were then patched onto LB agar 
plates containing either Cm or Km, with an expected CmS and KmR phenotype for 
mutants with lpxO replaced by the Km cassette and no autonomously replicating 
plasmids. Having achieved the appropriate KmR and CmS phenotype, PCR screens 
using primers specific for different possible Km cassette orientations were performed 
to confirm cassette integration and gene loss (Figure 7; Table 3). 
The final stage of generating ΔlpxO and ΔphoPQ mutants required removal of the 
Km cassette with pCP20. The pCP20 plasmid possesses the Flp gene, encoding an 
FLP recombinase that removes the cassette from between the cassette’s FRT 
flanking regions. Its removal would be the final step of mutant generation, ensuring 
that any phenotypes arising during antimicrobial susceptibility testing were a result 
of gene deletion, not an artefact of the Km cassette.  
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5.1.3. Challenges faced during mutant construction 
Unfortunately, despite numerous attempts to generate these mutants, PCR screens 
for the presence of the cassette and the absence of either lpxO or phoPQ could not 
be confirmed, and the cassette removal stage was never reached. On several 
occasions, an unsuccessful exchange was confirmed due to the retention of CmR. 
However, from the majority of attempts, despite precisely following the temperature-
specific steps which should select for correct integrants, and even though the KmR 
and CmS phenotype was observed implying a successful exchange, genotypic tests 
could not confirm gene knockout. PCR screens to detect the Km cassette either 
failed to generate bands, or resulted in aspecific amplification that did not produce 
an expected PCR product size, indicating an unsuccessful exchange. In addition, 
follow-up PCRs with lpxO qPCR primers produced band sizes equivalent to <200 
bp, comparable to the w/t positive control and indicative of gene presence. PCR 
screens were conducted multiple times using different machines to rule out 
equipment as the reason behind unsuccessful genotypic confirmation. Furthermore, 
phenotypic assessments were carried out for several of the putative mutants, for 
which PCR screens could not confirm gene loss. Antimicrobial susceptibility assays 
performed by agar dilution and disk diffusion methods on these strains showed 
values indistinguishable from w/t Ecl8. 
The study from which the exchange protocol originates [217] reported a high 
protocol efficacy and success rate, whilst one of the paper’s authors also confirmed 
no struggles generating mutants with the protocol (McAteer, S., Aug 2016, personal 
communication). Furthermore, the study’s citation index demonstrates that the 
protocol is successfully reproducible [217]. Moreover, previous studies have 
demonstrated an ability to generate both lpxO and phoPQ inactivated mutants [183, 
191, 222, 223], indicating that these genes are not essential for bacterial survival. As 
a result we continued to persevere with the protocol in an effort to generate mutants, 
but despite alterations to the protocol, such as maintaining antibiotic selection 
throughout, and direct training at the source laboratory where the method was 
developed, we did not achieve the desired outcome. As mutants had previously 
been successfully generated in K. pneumoniae Ecl8 using the same exchange 
protocol, including in our laboratory, we identified environmental conditions as a 
possible hurdle. We first confirmed that the incubators required for temperature-
sensitive steps of the protocol were functioning correctly. We then began with fresh 
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reagents, including new LB broth and agar. However, none of these approaches 
succeeded in resolving the situation. Because the nature of the environmental 
conditions that might have been affecting the protocol’s efficacy could not be 
pinpointed, we consequently attempted the exchange protocol in an external 
laboratory where mutants had been successfully generated in the past. Despite 
producing isolates with an appropriate KmR phenotype, PCR screens again showed 
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5.2. Construction of complementation plasmids 
As a result of our struggles to generate lpxO and phoPQ knockout mutants in Ecl8 
and Ecl8ΔramR, we set about with an adapted plan to examine the role of lpxO in 
the K. pneumoniae AMR phenotype. We had struggled to generate knockout 
mutants to analyse the effect of lpxO gene absence on resistance, therefore the new 
approach assessed if overexpression of the lpxO gene alone could affect 
susceptibility to the last-line drugs PxB, colistin, and tigecycline. These antimicrobial 
agents were selected due to the previously reported role of ramA overexpression in 
mediating resistance to tigecycline [134, 135, 143], and the impact of both ramA and 
phoPQ expression on reducing susceptibility to PxB and colistin [1, 177, 183, 196-
199, 211]. Therefore, we sought to directly compare the effects of ramA, phoP and 
lpxO overexpression on susceptibility to these agents when introduced into the w/t 
Ecl8 and the ramA overexpressor Ecl8ΔramR. We predicted that lpxO 
overexpression would reduce susceptibility to PxB and colistin, consistent with 
previous studies where lipid A modifications reduce the negative charge of the OM 
and limit the efficacy of CAMP binding and OM permeabilisation [176, 177, 183, 
211]. While not fully representative of intrinsic naturally induced gene 
overexpression, our approach involved constructing ramA, phoP and lpxO 
overexpression plasmids, using vectors with established copy numbers, and 
assessing the direct effect of increased gene expression on bacterial susceptibility to 
PxB, colistin and tigecycline.  
The construction of these overexpression plasmids also fulfilled a dual role as 
complementation plasmids. This was in the event that we successfully generated 
lpxO and phoPQ knockout mutants; we would need to confirm that any phenotypes 
observed as a result of gene loss could be recovered by the gene’s re-introduction. 
Unfortunately, we were unable to utilise these plasmids for complementation due to 
the inability to generate knockout mutants. 
5.2.1. Ecl8/pAClpxO and Ecl8ΔramR/pAClpxO: lpxO overexpression in K. 
pneumoniae 
Plasmid copy number refers to the average number of plasmid copies in the 
bacterial cell, and is dependent on plasmid size and the size of the inserted gene, as 
well as the plasmid’s origin of replication. For the purposes of our experiments, we 
aimed to increase lpxO levels via overexpression using a low copy plasmid. We did 
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not want to overwhelm the bacteria carrying the construct with an unnaturally high 
level of lpxO as doing so could potentially result in erroneous phenotypes consistent 
with the stress response e.g. structural issues within the bacterium but not actual 
functional phenotypes. Based on our requirements, we chose pACYC184 for our 
destination vector, which would carry the lpxO insert and be used in later 
antimicrobial susceptibility assays. pACYC184 is a pACYC plasmid; these plasmids 
are classed as low copy number with between ten to twelve copies per cell [224]. 
To generate our plasmid constructs, we first created the lpxO insert by amplifying 
the lpxO gene from Ecl8 genomic DNA using primers with EcoRI and ScaI restriction 
sites specific to our final pACYC184 destination vector (Table 3). The lpxO insert 
was next ligated into the pJET cloning vector and transformed into E. coli DH10β 
cells via heat-shock transformation. Resulting transformants were picked and 
screened by colony PCR with lpxO- or pJET vector-specific primers to determine 
whether a successful ligation between insert and vector had taken place. Following 
this, the pJETlpxO plasmid was extracted and restriction digests performed using 
the primer-specific EcoRI and ScaI restriction sites to release the fragment. 
Following gel extraction, the lpxO fragment was successfully ligated into pACYC184, 
transformed into E. coli DH10β, and the subsequent transformants then screened. 
pACYC184 possesses both tetracycline (Tc) and Cm resistance genes. The excision 
of pACYC184 with EcoRI and ScaI and subsequent ligation of the lpxO insert 
disrupts the Cm resistance gene; therefore the transformants were screened using 
the phenotypic loss of CmR and PCR presence of the lpxO insert. 
To assess the effect of lpxO overexpression in K. pneumoniae, pAClpxO was 
extracted from DH10β/pAClpxO, with a small amount taken aside and digested with 
EcoRI and ScaI to confirm the presence of the lpxO insert. The remaining plasmid 
was introduced into Ecl8 and Ecl8ΔramR by electroporation and selected for using 
Tc. In order to determine whether any observed effects from subsequent 
antimicrobial susceptibility experiments were a result of increased lpxO expression 
or from the influence of the vector, we set up plasmid-only controls. pACYC184 from 
laboratory stocks was extracted and transformed into Ecl8 and Ecl8ΔramR by 
electroporation. TcR transformants were picked and stored for later use as controls. 
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5.2.2. Ecl8/pBRlpxO and Ecl8ΔramR/pBRlpxO: further increasing lpxO levels 
In addition to pAClpxO, we wanted to generate an alternative lpxO overexpression 
construct with a higher copy number, in case the lpxO increase mediated by 
pAClpxO failed to influence an AMR phenotype. We therefore selected pBR322, a 
medium copy number plasmid generating between fifteen to twenty copies per cell 
[224]. pBR322 from laboratory stocks was extracted and digested using the primer-
specific EcoRI and ScaI restriction enzymes, while pAClpxO was simultaneously cut 
with the same enzymes. Following gel extraction the lpxO fragment was ligated into 
pBR322 and transformed into E. coli DH10β, with transformants subsequently 
screened. pBR322 possesses both ampicillin (Amp) and Tc resistance genes. The 
excision of pBR322 with EcoRI and ScaI and subsequent ligation of the lpxO insert 
disrupts the Amp resistance gene; therefore the transformants were screened for a 
TcR and AmpS phenotype and PCR presence of lpxO. The pBRlpxO construct was 
then extracted from DH10β/pBRlpxO and electroporated into Ecl8 and Ecl8ΔramR; 
a TcR and AmpS phenotype confirmed the successful transformation. Plasmid-only 
controls were also set up, where pBR322 was electroporated into Ecl8 and 
Ecl8ΔramR, with successful clones selected for with Tc. 
5.2.3. Ecl8/pACphoP and Ecl8ΔramR/pACphoP: phoP overexpression in K. 
pneumoniae 
In order to assess the effect of phoP overexpression on reduced antimicrobial 
susceptibility, we first had to generate the plasmid construct similarly to pAClpxO. 
However, pACphoP proved considerably more difficult to generate. Originally, the 
phoP insert was amplified from Ecl8 genomic DNA, using primers with EcoRI and 
ScaI restriction sites specific to pACYC184 (Table 3), and ligated into pJET. Despite 
the relative ease with which the lpxO insert had ligated into this vector, upon 
transformation of pJETphoP into E. coli DH10β, transformants consistently failed to 
grow. As a result, we resorted to changing our vector to the pGEM-T Easy cloning 
system. This required an intermediary step prior to ligation to A-tail our phoP insert. 
This was because the initial phoP insert was amplified with Q5 proof-reading 
polymerase which generates blunt ends, whereas the pGEM-T Easy vector requires 
an A-tailed insert for ligation. Following transformation into DH10β, colony PCR 
screening of resulting transformants with amplification primers confirmed the 
presence of phoP. Subsequent digests of extracted pGEM-T EasyphoP and the 
destination vector pACYC184 with primer-specific EcoRI and ScaI were followed by 
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ligation and transformation into DH10β. Transformants were selected for using Tc, 
with a TcR phenotype confirming a successful ligation, and the plasmid was then 
extracted and electroporated into Ecl8 and Ecl8ΔramR. No control strains had to be 
generated for pACphoP due to the Ecl8/pACYC184 and Ecl8ΔramR/pACYC184 
strains already established alongside pAClpxO generation. 
5.2.4. Ecl8/pACramA and Ecl8ΔramR/pACramA: ramA overexpression in K. 
pneumoniae 
In order to assess the effect of ramA on antimicrobial susceptibility, we needed to 
compare the lpxO and phoPQ overexpression constructs with a similarly generated 
ramA-overexpressing construct. Fortunately, pACramA had been previously 
constructed, therefore it was extracted from lab stocks and electroporated into Ecl8 
and Ecl8ΔramR. Controls were established in order to determine any influence from 
the pACramA vector on susceptibility results; pACYC177 from lab stocks was 
extracted and electroporated into Ecl8 and Ecl8ΔramR. Ecl8 and Ecl8ΔramR 
transformants with pACramA and pACYC177 were selected for using Km; a KmR 
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5.3. Resistance phenotypes of different mutants and 
overexpression constructs 
In order to define the contribution of lpxO to K. pneumoniae RamA-mediated AMR, 
and to determine any potential role for phoPQ in this phenotype, we performed 
antimicrobial susceptibility experiments. These consisted of MICs and relative 
survival assays (RSAs), which allowed the direct comparison of the susceptibility of 
strains overexpressing lpxO, ramA, or phoPQ, or with various RamA-regulated 
resistance genes knocked out. The subsequent relative susceptibility of these 
strains to PxB and colistin would provide indications as to the role of specific genes 
in generating resistance to polymyxin antibiotics. In addition, we were keen to 
assess the susceptibility of our strains to tigecycline for two reasons. Firstly, due to 
the established role of RamA and AcrAB in conferring resistance to tigecycline [126, 
225-230], we aimed to use tigeycline as a control; to validate our strains and plasmid 
constructs by comparing reported phenotypes with our own outcomes. Secondly, as 
described previously, tigecycline is a drug of increasing interest in the treatment of 
MDR K. pneumoniae as it retains good effectiveness against β-lactamase producing 
strains [144-146]. Therefore, examining mechanisms that contribute to tigecycline 
resistance is important in order to determine how to make this agent more effective.  
In order to characterise the roles of our overexpressed genes, we needed to perform 
antimicrobial susceptibility experiments with a variety of K. pneumoniae strains. 
These were either the w/t Ecl8, strains possessing our gene-overexpression 
plasmids, or knockout mutants with a Km cassette replacing genes identified to be 
important in the RamA-mediated AMR phenotype. We performed both MIC 
experiments and RSAs in order to rigorously examine antimicrobial susceptibility 
phenotypes. RSAs are useful to investigate antimicrobial susceptibility as they are 
understood to provide an advantage to the drug in killing bacteria. Therefore RSAs 
allowed us to characterise and assess the ability of genes to promote bacterial 
survival under bactericidal challenge. MICs on the other hand provide an advantage 
to the bacteria, as the aim of these experiments is to assess bacterial growth 
inhibition, as opposed to bacterial survival. For these reasons we performed both 
MICs and RSAs to thoroughly characterise lpxO, ramA and phoP overexpression 
from a position of advantage to both the bug and the drug, and therefore provide 
extra support to any susceptibility trends observed. 
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MICs to tigecycline, PxB and colistin were tested by the doubling agar dilution 
method as described previously [220, 221]. Diluted bacterial cultures were 
inoculated on antibiotic-containing LB agar, grown overnight at 37°C, and assessed 
the next day for the concentration at which growth was inhibited. The concentrations 
of tigecycline tested ranged from 0.0156 mg/L to 4 mg/L; the concentrations tested 
for PxB and colistin ranged from 0.0156 mg/L to 1 mg/L. Between 0.0156 mg/L and 
0.5 mg/L, each concentration increased by approximately 75%; between 0.5 mg/L 
and 4 mg/L, concentrations doubled (Table 5). Strains were tested in duplicate, and 
in some cases exhibited more than one MIC value. Therefore in-text references to 
MIC values use the highest concentration that was observed. 
RSAs were conducted to assess the ability of lpxO, ramA and phoP overexpression 
to promote bacterial survival following exposure to increasing concentrations of PxB 
and colistin. RSAs were performed as described previously [219]: briefly, overnight 
cultures were incubated with or without antibiotics for one hour at 37°C, then serially 
diluted and spread on LB agar plates. After overnight incubation at 37°C, single 
colonies were counted and the CFU/ml calculated to 105. The relative survival was 
calculated as a percentage of the CFU/ml of surviving exposed bacteria at each 
concentration compared to corresponding unexposed bacteria. This assay provides 
an analysis of how specific genes contribute to survival in the face of intensifying 
antimicrobial pressure. 
5.3.1. Characterising the contribution of ramA and RamA-regulated 
permeability genes to tigecycline, PxB and colistin susceptibility 
Overexpression of ramA has been reported to mediate a MDR phenotype via its 
regulation of bacterial permeability genes [1, 125, 140], resulting in reduced 
susceptibility to tigecycline, PxB and colistin [1, 134, 135, 143]. To confirm these 
previous findings [1, 134, 135, 143], we tested w/t Ecl8, ramA-overexpressing 
Ecl8ΔramR, and the ramA-deleted Ecl8ΔramA. These also acted as controls to 
compare other tested strains to. We also included Ecl8<ramA>Km, 
Ecl8<romAramA>Km, and Ecl8<ramR>Km, generated previously in the lab using 
the Km cassette exchange protocol. Both sets of marked and unmarked deletion 
strains were tested to determine if there were any differences in susceptibility; to 
assess if the presence of the Km cassette has any influence on the bacterial 
susceptibility phenotype. Because we wanted to test the effect of plasmid-mediated 
lpxO and phoP overexpression, we also included Ecl8/pACramA and 
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Ecl8ΔramR/pACramA, as well as the Ecl8/pACYC177 and Ecl8ΔramR/pACYC177 
vector-only controls. This allowed us to directly compare the influence of the three 
genes of interest – lpxO, phoP, and ramA – using the same plasmid-mediated 
expression mechanism.  
In addition we tested knockout mutants of several RamA-regulated, resistance-
associated permeability genes in the AMR phenotype, which had previously been 
generated using the Km cassette exchange protocol. The AcrAB-TolC efflux pump 
has been strongly linked with AMR due to alterations in efflux activity [122, 148] and 
is regulated at gene level by RamA [1]. We tested the susceptibility of 
Ecl8<acrAB>Km, Ecl8ΔramR<acrAB>Km, Ecl8<tolC>Km, and Ecl8ΔramR<tolC>Km 
in order to define which of the acrAB and tolC efflux genes might be most crucial to 
promoting reduced drug susceptibility. We also tested knockout mutants of the porin 
genes ompC and ompF – Ecl8<ompC>Km, Ecl8ΔramR<ompC>Km, 
Ecl8<ompF>Km, and Ecl8ΔramR<ompF>Km – due to their regulation by RamA [1, 
140, 231] and their role in MDR, where their decreased expression leads to reduced 
influx [105, 152, 232, 233]. 
5.3.1.1. Overexpression of ramA the key factor in reducing susceptibility to 
tigecycline 
MIC experiments exposing various K. pneumoniae strains to tigecycline 
demonstrate that ramA overexpression dramatically reduces susceptibility (Figure 9; 
Table 6). In Ecl8 and Ecl8ΔramA (MIC = 0.25 mg/L and 0.1875 mg/L respectively), 
the MICs were approximately ten-fold lower than Ecl8ΔramR (MIC = 2 mg/L). These 
MIC values were reinforced by similar differences between Ecl8<ramR>Km (MIC = 2 
mg/L), and Ecl8<ramA>Km and Ecl8<romAramA>Km (MIC = 0.1875 mg/L for both). 
Indeed, with a few exceptions, strains with an Ecl8ΔramR background where ramA 
is chromosomally overexpressed display a ten-fold higher MIC value compared to 
Ecl8, Ecl8ΔramA, Ecl8<ramA>Km and Ecl8<romAramA>Km. Corresponding to the 
report by Majumdar et al. [1], we show that ramA inactivation does not appear to 
substantially reduce tigecycline susceptibility compared to w/t Ecl8. Additionally, 
retention of the Km cassette appeared to have no significant effect on the 
susceptibility phenotype, as seen by the similar MICs of the different ramR 
knockouts, and the various ramA knockout strains. 
 






















































































































































































































































































































































































K. pneumoniae strains 
Tig
Figure 9. MIC of K. pneumoniae Ecl8 w/t and mutant strains to tigecycline. MICs are 
presented as an average of the experimentally derived results. Each strain was tested at 






















Notably, Ecl8/pACramA (MIC = 0.1875 mg/L) and Ecl8ΔramR/pACramA (2 mg/L) 
possessed the same MIC values as Ecl8 and Ecl8ΔramR respectively (Figure 9; 
Table 6). In addition, the MICs of Ecl8/pACramA and Ecl8ΔramR/pACramA were 
identical to the corresponding pACYC177 controls. Due to the established role of 
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ramA overexpression in conferring tigecycline resistance [134, 135, 143], and based 
on our own observations of this contribution, it seemed unusual that plasmid-
mediated ramA overexpression was unable to further reduce susceptibility. This 
might indicate a problem with the generation of our pACramA strains, or could be 
because the pACramA plasmid incurs a fitness cost when introduced into the K. 
pneumoniae strain [234].  
The RamA-regulated AcrAB-TolC efflux pump is an important component of RamA-
mediated resistance to tigecycline [227, 228, 235-237]. Here we show that tolC and 
acrAB knockout mutants in the w/t Ecl8 background exhibit a minor increase in 
susceptibility compared to Ecl8 (Figure 9; Table 6). Notably, two exceptions to the 
observation that strains with an Ecl8ΔramR background are more resistant than w/t 
Ecl8 are Ecl8ΔramR<tolC>Km and Ecl8ΔramR<acrAB>Km. Compared to the high 
MIC of Ecl8ΔramR (MIC = 2 mg/L), Ecl8ΔramR<tolC>Km and 
Ecl8ΔramR<acrAB>Km are significantly more susceptible, with MIC values 20-fold 
lower (MIC = 0.094 mg/L for both) (Figure 9; Table 6). This indicates that the acrAB 
and tolC genes are important components of the RamA-regulated tigecycline 
resistance phenotype, consistent with previous findings [227, 228, 235-237], but 
does not elucidate which, if any, of these two genes is most vital to reducing 
tigecycline susceptibility. No differences were seen for ompC or ompF knockout 
mutants compared to the corresponding Ecl8 or Ecl8ΔramR controls, except 
Ecl8<ompF>Km which demonstrated reduced susceptibility compared to w/t Ecl8 
(MIC = 0.375 mg/L and 0.25 mg/L respectively). This corresponds to previously 
reported AMR phenotypes resulting from decreased ompF expression, which leads 
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Table 6. MIC of K. pneumoniae Ecl8 w/t and mutant strains to PxB, colistin, and 
tigecycline 
Strains PxB (mg/L) Colistin (mg/L) Tigecycline (mg/L) 
Ecl8 0.1875
2
 0.094 – 0.1875
2
 0.1875 – 0.25
2
 
Ecl8ΔramA 0.125 – 0.1875
2





























































Ecl8<acrAB>Km 0.1875 – 0.25
2









 0.0625 – 0.094
1
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Table 6. Each strain was tested at least once, in duplicate. For in-text referencing of MIC 
values, the higher MIC is used. 
1
 Strains were tested once, in duplicate; 
2
 strains were 
tested twice, each time in duplicate; 
3
 strains were tested on three occasions, each time 
in duplicate. 
 
Ecl8/pACYC177 0.125 – 0.1875
2












Ecl8/pACphoP 0.5 - 1
1



















Ecl8∆ramR/pAClpxO 0.1875 – 0.25
1





Ecl8/pACYC184 0.125 – 0.1875
2













































5.3.1.2. Overexpression of ramA confers minimal resistance to PxB and 
colistin 
In K. pneumoniae, ramA overexpression has previously been reported to mediate a 
reduction in susceptibility to both PxB and Colistin [1]. From our MIC experiments 
(Figure 10; Table 6), we show that in response to PxB exposure, ramA-
overexpressing Ecl8ΔramR and Ecl8<ramR>Km have a 1.3-fold higher MIC (MIC = 
0.25 mg/L for both) than Ecl8, Ecl8ΔramA, Ecl8<ramA>Km and 
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Ecl8<romAramA>Km (MIC = 0.1875 mg/L for all). These results show that ramA 
overexpression conferred a slight reduction in susceptibility to PxB; however ramA 
inactivation did not increase susceptibility. MICs after colistin exposure gave mixed 
results (Figure 10; Table 6). Ecl8<ramR>Km (MIC = 0.1875 mg/L) had a 1.5-fold 
higher MIC than Ecl8<ramA>Km and Ecl8<romAramA>Km (MIC = 0.125 mg/L for 
both), but presented the same MIC value as Ecl8, Ecl8ΔramA and Ecl8ΔramR (MIC 
= 0.1875 mg/L for all). 
Similarly to tigecycline MICs, the introduction of pACramA into Ecl8 and Ecl8ΔramR 
made no difference to PxB susceptibility, with these strains possessing the same 
MIC values as the corresponding Ecl8/pACYC177 and Ecl8ΔramR/pACYC177 
vector-only controls (MIC = 0.1875 mg/L and 0.25 mg/L respectively) (Figure 10; 
Table 6). pACramA also had no effect in reducing susceptibility to colistin (Figure 10; 
Table 6); interestingly, introduction of pACYC177 into Ecl8ΔramR increased 
susceptibility. Because of the reported role of ramA overexpression in conferring 
tigecycline, PxB, and colistin resistance [1, 134, 135, 143], it is surprising that 
introduction of pACramA into our strains was unable to reduce susceptibility to any 
of these drugs.  
Indeed, from the RSA results (Figures 11 and 12), Ecl8/pACramA and 
Ecl8ΔramR/pACramA did not show any ability to reduce susceptibility to PxB or 
colistin. In fact, the only strains showing a statistically significant relative survival 
percentage after PxB exposure were Ecl8ΔramR at 0.033 μg/ml (8.27 %), and 
Ecl8ΔramR/pACYC177 at 0.033 μg/ml and 0.064 μg/ml (7.26 %  and 1.41 % 
respectively). Following colistin treatment, the only statistically significant survival 
was by Ecl8ΔramR at 0.033 μg/ml (9.8 %), Ecl8ΔramR/pACYC177 at 0.033 μg/ml 
and 0.096 μg/ml (3.63% and 0.07 % respectively), and Ecl8ΔramR/pACramA at 
0.064 μg/ml (0.73 %). It is unusual that the pACramA construct was unable to confer 
resistance to PxB, and while Ecl8ΔramR/pACramA did demonstrate survival after 
colistin treatment, it is more likely that this effect was a result of the Ecl8ΔramR 
background. The proposed ineffectiveness of pACramA is supported by the MIC 
values of the pACramA strains for all the antibiotics tested. It is further reinforced by 
the RSA results, where the Ecl8ΔramR/pACYC177 control possesses a similar 
ability to survive PxB and colistin exposure as Ecl8ΔramR/pACramA. It is therefore 
likely that the survival demonstrated by strains in the RSAs is a result of the 
chromosomal ramA expression present in Ecl8ΔramR. Indeed, all of the strains that 



















































































































































































































































































































































































K. pneumoniae strains 
PxB Col
Figure 10. MICs of K. pneumoniae Ecl8 w/t and mutant strains to PxB and Colistin. MICs 
are presented as an average of the experimentally derived results. Each strain was tested at 
least once, in duplicate. Error bars show the standard deviation of samples’ MIC values. 
 
displayed statistically significant survival after PxB or colistin exposure had an 
Ecl8ΔramR background in common, thus supporting previous data that ramA 
overexpression does confer protection against PxB and colistin killing. Furthermore, 
in subsequent RSAs testing pAClpxO and pACphoP strains (Figures 13 and 14) 

















































PxB concentration (µg/ml) 
Ecl8 Ecl8ΔramR Ecl8/pACramA
Ecl8ΔramR/pACramA Ecl8/pACYC177 Ecl8ΔramR/pACYC177 
Figure 11. Relative survival assay of K. pneumoniae (Ecl8 w/t, mutant, pACramA, 
pACYC177 strains) to PxB. Bacteria were incubated stationary, with or without PxB, for 1 hour 
at 37°C before being serially diluted and 50 µl spread on LB agar half-plates in duplicate. After 
overnight incubation at 37°C, single colonies were counted and CFU/ml calculated to 10
5
. The 
relative survival was calculated as a percentage of surviving exposed bacteria compared to 
corresponding unexposed bacteria. Error bars show the standard deviation of the relative 
survival percentages derived from the replicates. Student’s T-test was performed on samples at 
each antibiotic concentration to determine if the CFU/ml was statistically significant compared to 
the w/t Ecl8 control at the same concentration: * for p <0.05, ** for p <0.005, *** for p <0.0005. 























































Colistin concentration (µg/ml) 
Ecl8 Ecl8ΔramR Ecl8/pACramA
Ecl8ΔramR/pACramA Ecl8/pACYC177 Ecl8ΔramR/pACYC177 
Figure 12. Relative survival assay of K. pneumoniae (Ecl8 w/t, mutant, pACramA, 
pACYC177 strains) to colistin. Bacteria were incubated stationary, with or without colistin, for 
1 hour at 37°C before being serially diluted and 50 µl spread on LB agar half-plates in duplicate. 
After overnight incubation at 37°C, single colonies were counted and CFU/ml calculated to 10
5
. 
The relative survival was calculated as a percentage of surviving exposed bacteria compared to 
corresponding unexposed bacteria. Error bars show the standard deviation of the relative 
survival percentages derived from the replicates. Student’s T-test was performed on samples at 
each antibiotic concentration to determine if the CFU/ml was statistically significant compared to 
the w/t Ecl8 control at the same concentration: * for p <0.05, ** for p <0.005, *** for p <0.0005. 
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The ΔacrAB and ΔtolC mutants produced mixed responses to PxB and colistin 
(Figure 10; Table 6). Of the ΔacrAB mutants, Ecl8<acrAB>Km (PxB and colistin MIC 
= 0.25 mg/L) possessed a 1.3-fold higher PxB and colistin MIC compared to Ecl8 
(PxB and colistin MIC = 0.1875 mg/L), whilst on the other hand 
Ecl8ΔramR<acrAB>Km (PxB MIC = 0.1875 mg/L; colistin MIC = 0.125 mg/L)  was 
approximately 1.3-fold more susceptible to both antimicrobials compared to 
Ecl8ΔramR and Ecl8<ramR>Km (PxB MIC = 0.25 mg/L for both; colistin MIC = 
0.1875 mg/L for both). Overexpression of ramA increases expression of acrA [1], 
and acrAB has been established as a critical component of RamA-mediated AMR [1, 
130, 150]. The difference in susceptibility between Ecl8ΔramR<acrAB>Km and 
Ecl8<acrAB>Km may be because basal ramA expression from the Ecl8 background 
does not significantly impact on acrAB expression, hence no decrease in 
susceptibility. However, deletion of acrAB in a ramA overexpressing background 
should impact on susceptibility, consistent with our findings where 
Ecl8ΔramR<acrAB>Km is more susceptible to PxB and colistin than Ecl8ΔramR.  
Ecl8<tolC>Km (MIC = 0.125 mg/L) was more susceptible to colistin than Ecl8 with a 
1.5-fold lower MIC. However, in response to PxB, MIC values of the two strains were 
the same. Ecl8ΔramR<tolC>Km PxB and colistin MICs did not differ from 
Ecl8ΔramR or Ecl8<ramR>Km, indicating that tolC is not an important component of 
the RamA-mediated PxB and colistin resistance phenotype. This could be because 
ramA overexpression upregulates other resistance genes, such as acrAB, which 
compensate for tolC loss and retain the ramA overexpression phenotype. In the 
case of the ΔompC and ΔompF mutants, no differences were seen in MICs 
compared to corresponding Ecl8 or Ecl8ΔramR controls, indicating no role for these 
porins in PxB or colistin resistance. 
5.3.2. Characterising regulation of lpxO overexpression and its impact on 
tigecycline, PxB and colistin susceptibility 
Specific LpxO-mediated lipid A modifications are associated with reduced 
susceptibility to colistin and CAMPs [183, 211]. The lpxO gene has been shown to 
be under the regulatory control of both the RamA transcription regulator and the 
PhoPQ TCS [1, 183, 209, 211]; the overexpression of either of these regulatory 
factors has also been linked to reduced polymyxin and CAMP susceptibility. RamA 
is also responsible for mediating a reduced susceptibility to tigecycline [134, 135, 
143], with RamA-regulated genes such as acrAB playing a key role, as reported 
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previously and observed in this study [227, 229, 236]. As a result, we sought to 
define what role lpxO overexpression plays in RamA-mediated responses to 
polymyxins and tigecycline; is it able to independently reduce polymyxin 
susceptibility, and does it feature significantly in reducing susceptibility to tigecycline. 
In order to assess the contribution of lpxO overexpression, we tested Ecl8/pAClpxO, 
Ecl8ΔramR/pAClpxO, Ecl8/pBRlpxO and Ecl8ΔramR/pBRlpxO, as well as the 
corresponding vector-only controls. We also tested the putative ΔlpxO mutants 
Ecl8<lpxO>Km and Ecl8ΔramR<lpxO>Km; this was a chance to phenotypically 
validate these putative ΔlpxO mutants because PCR screens appeared to confirm 
presence of the lpxO gene (Figure 8). As putative ΔlpxO mutants, we would expect 
to see lpxO loss lead to an increase in susceptibility to polymyxins, as LpxO-
mediated lipid A modifications reduce susceptibility to colistin and CAMPs [183, 
211]. 
5.3.2.1. Overexpression of lpxO reduces tigecycline susceptibility 
The results of strains overexpressing lpxO were mixed (Figure 9; Table 6). The MIC 
of Ecl8/pAClpxO (MIC = 2 mg/L) was ten-fold that of Ecl8 (MIC = 0.25 mg/L). 
However, this MIC value was identical to that of the Ecl8/pACYC184 vector-only 
control (MIC = 2mg/L), indicating that the reduced susceptibility was associated with 
the plasmid, as opposed to overexpressed lpxO. Ecl8ΔramR/pAClpxO on the other 
hand demonstrated an MIC value (MIC = 4 mg/L) double that of Ecl8ΔramR (MIC = 
2 mg/L) and the Ecl8ΔramR/pACYC184 control (MIC = 2 mg/L), suggesting that 
overexpressed lpxO elevates the RamA-mediated response to tigecycline in K. 
pneumoniae. 
Ecl8/pBRlpxO showed a slight reduction in susceptibility to tigecycline compared to 
Ecl8 (1.5-fold); however Ecl8/pBR322 demonstrated an even greater decrease (4-
fold). This suggests that reduced susceptibility was conferred by pBR322, not lpxO 
overexpression. In support of this, neither Ecl8ΔramR/pBRlpxO nor the 
Ecl8ΔramR/pBR322 control displayed any reduction in susceptibility compared to 
Ecl8ΔramR. 
The original putative ΔlpxO mutants, Ecl8<lpxO>Km and Ecl8ΔramR<lpxO>Km, 
showed a contrastingly high level of resistance compared to any other strain tested 
except the similarly resistant Ecl8ΔramR/pAClpxO (Figure 9; Table 6). This was 
unexpected due to previous studies showing that decreased antimicrobial 
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susceptibility results from LpxO-mediated lipid A modifications [183, 211]. However, 
these observations were based on susceptibility to CAMPs and not tigecycline, 
therefore the role of lpxO deletion on tigecycline resistance may be different. LpxO-
mediated lipid A modifications may potentially contribute to antimicrobial 
susceptibility differently in an antimicrobial-dependent manner. Nonetheless, the 
similar MICs of lpxO overexpressing Ecl8ΔramR/pAClpxO, and the ΔlpxO mutants – 
Ecl8<lpxO>Km and Ecl8ΔramR<lpxO>Km – suggest that these mutants were in fact 
not successfully generated, as indicated by the original PCR validation (Figure 8). 
5.3.2.2. Characterisation of the role of lpxO overexpression in polymyxin 
resistance is inconclusive 
Overexpression of lpxO generated by the pAClpxO construct in Ecl8 and Ecl8ΔramR 
did not appear to reduce susceptibility to either PxB or colistin (Figure 10; Table 6). 
PxB MICs were the same between Ecl8/pAClpxO and Ecl8 (MIC = 0.1875 mg/L for 
both), and Ecl8ΔramR/pAClpxO and Ecl8ΔramR (MIC = 0.25 mg/L for both). The 
MIC of the Ecl8/pACYC184 control also corresponded to Ecl8/pAClpxO and Ecl8; 
however, Ecl8ΔramR/pACYC184 had a 1.3-fold lower MIC than 
Ecl8ΔramR/pAClpxo and Ecl8ΔramR, suggesting that the vector might incur a 
fitness cost. Colistin MICs followed a similar pattern, where pAClpxO conferred no 
reduction in susceptibility in Ecl8 and Ecl8ΔramR, and the Ecl8ΔramR /pACYC184 
control had a 1.5-fold lower MIC than Ecl8ΔramR /pAClpxO and Ecl8ΔramR (Figure 
10; Table 6). 
RSA results showed that, with one exception, pAClpxO strains did not reduce 
susceptibility to PxB or colistin (Figures 13 and 14). The exception was 
Ecl8/pAClpxO, which displayed statistically significant survival after exposure to 
0.033 μg/ml of colistin (53.86 %) (Figure 14). Ecl8/pAClpxO survival at 0.033 μg/ml 
was greater than both the Ecl8/pACYC184 control (0.82%) and the statistically 
insignificant survival of w/t Ecl8 (1.75%). In contrast Ecl8ΔramR/pAClpxO, though 
statistically significant, only displayed a survival percentage of 0.6 % which was 11-
fold lower than that of Ecl8ΔramR (6.74%). At higher concentrations of PxB and 
colistin pAClpxO and pACYC184 strains were unable to survive, except for the 
statistically significant survival of the ramA overexpressing Ecl8ΔramR/pACYC184 
at 0.096 μg/ml of PxB (0.24%) (Figure 13). These RSA results are inconclusive; the 
greater survival of Ecl8/pAClpxO compared to Ecl8ΔramR/pAClpxO suggests that 
ramA overexpression does not reduce colistin susceptibility. However, this is 
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Figure 13. Relative survival assay of K. pneumoniae (Ecl8 w/t, mutant, pAClpxO, 
pACphoP, pACYC184 strains) to PxB. Bacteria were incubated stationary, with or without PxB, 
for 1 hour at 37°C before being serially diluted and 50 µl spread on LB agar half-plates in 
duplicate. After overnight incubation at 37°C, single colonies were counted and CFU/ml 
calculated to 10
5
. The relative survival was calculated as a percentage of surviving exposed 
bacteria compared to corresponding unexposed bacteria. Error bars show the standard deviation 
of the relative survival percentages derived from the replicates. Student’s T-test was performed 
on samples at each antibiotic concentration to determine if the CFU/ml was statistically 
significant compared to the w/t Ecl8 control at the same concentration: * for p <0.05, ** for p 





































PxB concentration (µg/ml) 
Ecl8 Ecl8ΔramA Ecl8ΔramR 
Ecl8/pAClpxO Ecl8ΔramR/pAClpxO Ecl8/pACphoP
Ecl8ΔramR/pACphoP Ecl8/pACYC184 Ecl8ΔramR/pACYC184 
possibly an anomaly, as we have demonstrated that ramA overexpression increases 
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Colistin concentration (µg/ml) 
Ecl8 Ecl8ΔramA Ecl8ΔramR 
Ecl8/pAClpxO Ecl8ΔramR/pAClpxO Ecl8/pACphoP
Ecl8ΔramR/pACphoP Ecl8/pACYC184 Ecl8ΔramR/pACYC184 
Figure 14. Relative survival assay of K. pneumoniae (Ecl8 w/t, mutant, pAClpxO, 
pACphoP, pACYC184 strains) to colistin. Bacteria were incubated stationary, with or without 
colistin, for 1 hour at 37°C before being serially diluted and 50 µl spread on LB agar half-plates 
in duplicate. After overnight incubation at 37°C, single colonies were counted and CFU/ml 
calculated to 10
5
. The relative survival was calculated as a percentage of surviving exposed 
bacteria compared to corresponding unexposed bacteria. Error bars show the standard 
deviation of the relative survival percentages derived from the replicates. Student’s T-test was 
performed on samples at each antibiotic concentration to determine if the CFU/ml was 
statistically significant compared to the w/t Ecl8 control at the same concentration: * for p <0.05, 
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Despite the higher copy number of the pBR322 construct, the PxB MIC value of 
Ecl8/pBRlpxO (MIC = 0.125 mg/L) was 1.5-fold lower than w/t Ecl8, and the 
Ecl8ΔramR/pBRlpxO PxB MIC (MIC = 0.1875 mg/L) was 1.3-fold lower than 
Ecl8ΔramR (Figure 10; Table 6). Interestingly, the MIC of Ecl8/pBR322 (MIC = 0.25 
mg/L) was 2-fold higher than Ecl8/pBRlpxO and Ecl8, whilst contrastingly 
Ecl8ΔramR/pBR322 (MIC = 0.1875 mg/L) was 1.3-fold more susceptible to PxB than 
Ecl8ΔramR. Similarly, pBRlpxO did not reduce susceptibility to colistin in Ecl8 or 
Ecl8ΔramR, whilst the Ecl8ΔramR/pBR322 control was again more susceptible than 
Ecl8ΔramR/pBRlpxO and Ecl8ΔramR (1.5-fold). The case may be that pBR322 is 
detrimental to the bacterium’s ability to grow, having a knock-on effect on the 
pBRlpxO construct and thereby affecting its performance in our antimicrobial 
susceptibility assays.  
We also tested the putative ΔlpxO strains Ecl8<lpxO>Km and Ecl8ΔramR<lpxO>km, 
finding that MIC values for PxB and colistin, were much greater than those for Ecl8 
and Ecl8ΔramR respectively (Figure 10; Table 6). This forms a pattern with the 
Ecl8<lpxO>Km and Ecl8ΔramR<lpxO>km results from tigecycline exposure, where 
unexpectedly high MICs were also observed (Figure 9; Table 6), and reinforces the 
observation that these putative mutants were not successfully generated.  
5.3.3. Characterisation of overexpression constructs in E. coli DH10β 
In order to transform our plasmid constructs into Ecl8 and Ecl8ΔramR, they first had 
to be transformed into E. coli DH10β. These construct-bearing strains were also 
exposed to tigecycline, PxB and colistin with MICs determined to test if our plasmid 
constructs could confer resistance comparable to K. pneumoniae w/t Ecl8, 
Ecl8ΔramA or Ecl8ΔramR strains. 
5.3.3.1. pAClpxO reduces susceptibility of E. coli DH10β to tigecycline 
The DH10β strains containing pACramA and pACYC177 constructs both presented 
tigecycline MICs of 0.125 mg/L, suggesting that pACramA-mediated ramA 
overexpression did not affect tigecycline susceptibility (Figure 15; Table 7). 
However, we have demonstrated that Ecl8ΔramR plays a major role in reducing 
tigecycline susceptibility, consistent with other reports [134, 135, 143], thus 
suggesting that the pACramA construct is erroneous. Only DH10β/pAClpxO (MIC = 
0.375 mg/L) demonstrated a reduction in tigecycline susceptibility compared to its 
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control, with a 3-fold greater MIC relative to DH10β/pACYC184 (MIC = 0.125 mg/L), 
and roughly 2-fold greater than Ecl8, Ecl8ΔramA, Ecl8<ramA>Km and 
Ecl8<romAramA>Km (Figure 15; Table 7). This indicates a potential role for lpxO 
expression in reducing susceptibility to tigecycline, consistent with the high MIC of 
Ecl8ΔramR/pAClpxO. The absence of a DH10β/pBR322 control prevents a full 
assessment of how DH10β/pBRlpxO affects susceptibly; however its 1.5-fold greater 
MIC value (MIC = 0.1875 mg/L) compared to DH10β/pACramA, DH10β/pACYC177 
and DH10β/pACYC184 (MIC = 0.125 mg/L for all) supports the implication of lpxO 
overexpression in reduced tigecycline susceptibility.  
However, when compared with Ecl8<ramR>Km and Ecl8ΔramR, the MIC of 
DH10β/pAClpxO was 5.3-fold lower, and DH10β/pBRlpxO 10.6-fold lower. These 
observations, allied to the low MICs of DH10β/pACramA, DH10β/pACYC177 and 
DH10β/pACYC184 – at least 1.5-fold lower than MICS of Ecl8, Ecl8ΔramA, 
Ecl8<ramA>Km or Ecl8<romAramA>Km – may have several reasons. E. coli may 
be inherently more susceptible to tigecycline compared to K. pneumoniae, or 
alternatively the introduction of the plasmids into DH10β may confer a fitness cost, 
affecting the organism’s growth and ability to resist in spite of the overexpression of 
resistance-associated genes [234]. Another reason for their ineffectiveness may be 
that the plasmid constructs, whilst phenotypically correct when generated, may not 
be successful gene overexpression constructs. An error in the plasmid sequence, for 
example, may result in lower amounts of gene product than expected. This theory is 
supported by the ineffectiveness of pACramA in reducing susceptibility to 
tigecycline, despite our results showing that chromosomal ramA expression in 


























Figure 15. MIC of K. pneumoniae Ecl8 w/t and mutant strains and E. coli DH10β plasmid 
constructs to PxB, colistin and tigecycline. MICs are presented as an average of the 
experimentally derived results. Each strain was tested at least once, in duplicate. Error bars 
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Table 7. Each strain was tested at least once, in duplicate. For in-text referencing of MIC 
values, the higher MIC is used. 
1
 Strains were tested once, in duplicate; 
2
 strains were 
tested twice, each time in duplicate; 
3
 strains were tested on three occasions, each time in 
duplicate. 
 
Table 7. MIC of K. pneumoniae Ecl8 w/t and mutant strains and E. coli DH10β plasmid 






5.3.3.2. pAClpxO reduces PxB and colistin susceptibility in E. coli DH10β 
pACramA failed to mediate a reduction in susceptibility to PxB and colistin when 
introduced into E. coli DH10β compared to the corresponding vector-only control 
Strains PxB (mg/L) Colistin (mg/L) Tigecycline (mg/L) 
Ecl8 0.1875
2
 0.094 – 0.1875
2
 0.1875 – 0.25
2
 
Ecl8ΔramA 0.125 – 0.1875
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(Figure 15; Table 7). DH10β/pBRlpxO also failed to reduce susceptibility compared 
to DH10β/pACramA, DH10β/pACYC177 and DH10β/pACYC184, though without a 
DH10β/pBR322 control we cannot draw any definitive conclusion as to its impact on 
susceptibility. In contrast, DH10β/pAClpxO (PxB and colistin MIC = 0.0312 mg/L) 
conferred a minor reduction in susceptibility compared to the DH10β/pACYC184 
control (PxB MIC = 0.0234 mg/L; colistin MIC = 0.0156 mg/L), implicating lpxO 
expression as an important contributor to this phenotype.  
Whilst the apparent ineffectiveness of pACramA and pBRlpxO may be due to faults 
in their construction, it may alternatively support the idea that DH10β is considerably 
more susceptible to these antimicrobials than K. pneumoniae. Our MIC and RSA 
results show that plasmid-mediated phoP overexpression in K. pneumoniae plays an 
important role in reducing susceptibility to PxB and colistin (Figures 10, 13 and 14; 
Table 6). Time permitting; it would therefore be interesting to assess the effect of 
pACphoP introduction into DH10β; to act as a control for the other plasmid 
constructs to investigate if DH10β/pACphoP is able to mediate a reduction in 
polymyxin susceptibility similar to that seen in K. pneumoniae. 
5.3.4. Characterisation of the role of phoP overexpression in tigecycline, PxB 
and colistin resistance 
The PhoPQ TCS plays an important role in promoting resistance in the face of 
challenge by polymyxins and host CAMPs [177, 183, 196-199, 211]. Of the PhoPQ 
TCS, phoP has been reported to be the driver of CAMP and polymyxin resistance 
when constitutively activated [198, 203, 204]. We therefore performed MIC and RSA 
experiments to characterise the role of phoP overexpression in tigecycline and 
polymyxin susceptibility; comparing its contribution to lpxO and ramA 
overexpression, and determining any correlation between lpxO- and phoP-mediated 
phenotypes that might indicate a role for PhoPQ regulation of lpxO. Ecl8/pACphoP 
and Ecl8ΔramR/pACphoP were included to assess whether increased phoP 
overexpression reduces susceptibility in w/t K. pneumoniae, or is able to further 
reduce susceptibility in ramA-overexpressing strains. Ideally, had their generation 
been successful, we would also have included ΔlpxO and ΔphoP mutants to 
compare how their inactivation affected susceptibility. We conducted tigecycline MIC 
experiments in fulfilment of our aim to characterise the role of ramA and RamA-
regulated permeability genes in reduced susceptibility to this drug. Despite a 
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literature search revealing no previously reported role for phoPQ overexpression in 
reduced tigecycline susceptibility, we also tested pACphoP strains to examine any 
potential role that phoP overexpression may play in this phenotype. 
5.3.4.1. Overexpression of phoP does not reduce tigecycline susceptibility 
To assess any potential role that phoP may play in RamA-mediated tigecycline 
resistance, phoP-overexpressing Ecl8 and Ecl8ΔramR were exposed to varying 
concentrations of tigecycline (Figure 9; Table 6). Although Ecl8/pACphoP shows an 
8-fold higher MIC (MIC = 2 mg/L) than w/t Ecl8 (MIC = 0.25 mg/L), the 
corresponding Ecl8/pACYC184 control also shows the same value (MIC = 2 mg/L), 
suggesting that the increased resistance is conferred by the plasmid, not the 
plasmid-mediated overexpression of phoP. In Ecl8ΔramR/pACphoP there is no 
increase in resistance compared to Ecl8ΔramR, whilst the Ecl8ΔramR/pACYC184 
control also shows the same value (MIC = 2 mg/L). Based on these results, we 
inferred that in K. pneumoniae, phoP does not have a measurable impact on 
tigecycline resistance.  
5.3.4.2. Overexpression of phoP drives polymyxin resistance 
Previous studies have reported that PhoPQ mediates resistance to PxB and colistin 
in K. pneumoniae by activating genes associated with lipid A modification [183, 196-
199, 211]. We show that phoP overexpression substantially increases resistance to 
both PxB and colistin independently of ramA or lpxO. For both PxB and colistin, 
Ecl8/pACphoP and Ecl8ΔramR/pACphoP produced much higher MIC values than 
Ecl8 and Ecl8ΔramR respectively, as well as pAClpxO- and pACramA-producing 
strains, and the corresponding pACYC184 controls (Figure 10; Table 6). For PxB, 
Ecl8/pACphoP produced a 5-fold higher MIC (MIC = 1 mg/L) than Ecl8 (MIC = 
0.1875 mg/L), whilst the MIC of Ecl8ΔramR/pACphoP (MIC = 1 mg/L) was 4-fold 
higher than Ecl8ΔramR (MIC = 0.25 mg/L). Similarly, in response to colistin, the MIC 
of Ecl8/pACphoP (MIC = 0.5 mg/L) was 2.6-fold that of Ecl8 (MIC = 0.1875 mg/L), 
whilst Ecl8ΔramR/pACphoP (MIC = 1 mg/L) was 5-fold that of Ecl8ΔramR (MIC = 
0.1875 mg/L). 
We also tested various existing S. Typhimurium knockout strains, where genes 
including ramR, ramA, phoP and phoPQ were inactivated (Figure 16; Table 8). In 
Salmonella, ramA and phoPQ have both been associated with MDR [125, 128, 129, 
177, 200]. We wanted to determine if a S. Typhimurium ΔramR mutant conferred a 
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similar susceptibility trend to corresponding K. pneumoniae ΔramR mutants. 
Comparisons between S. Typhimurium w/t 4/74 and 4/74ΔramR showed that ramA 
overexpression did not reduce susceptibility to PxB and colistin, as occurs with ramA 
overexpression in K. pneumoniae Ecl8. In fact, in 4/74ΔramRA, the absence of the 
ram operon did not increase susceptibility. We also wanted to assess the impact of 
phoP and phoPQ loss on S. Typhimurium polymyxin susceptibility. S. Typhimurium 
4/74ΔphoPΔramR, 4/74ΔphoPΔramRA, and 4/74ΔphoPQ (PxB MIC = 0.0468 mg/L 
for all; colistin MIC = 0.0234 mg/L for all) all demonstrated a 4-fold increase in 
susceptibility compared to w/t S. Typhimurium (PxB and colistin MIC = 0.1875 
mg/L), and a minimum 5.3-fold increase compared to the tested K. pneumoniae 
strains, indicating the importance of phoP in mediating survival. Ideally we would 
also test K. pneumoniae ΔphoPQ mutants, instead of relying on interpretations 
about the importance of phoPQ from Salmonella; however, generating these 
mutants proved unsuccessful. Because phoPQ has been shown to be important in 
K. pneumoniae AMR [183, 211], as it is in Salmonella [177, 200], interpretations 
concerning the significance of PhoPQ are likely to be consistent between these two 
species. 
The PxB and colistin RSAs confirm that of the various genes we tested, phoP was 
the key driver of resistance to these agents (Figures 13 and 14). Despite several 
strains exhibiting survival at 0.033 μg/ml of PxB and colistin, the only strains 
showing statistically significant survival up to and including the highest 
concentrations tested were Ecl8/pACphoP and Ecl8ΔramR/pACphoP. The 
corresponding pACYC184 controls showed no survival at high antibiotic 
concentrations, bar the survival of Ecl8ΔramR/pACYC184 at 0.096 μg/ml of PxB, 
signifying that the pACphoP resistance phenotypes were phoP-dependent and not 
an influence of the vector. This indicates that, of the various genes we tested, 
resistance to PxB and colistin is primarily influenced by phoP. Interestingly, of 
Ecl8/pACphoP and Ecl8ΔramR/pACphoP, the former demonstrates consistently 
higher survival across increasing PxB and colistin concentrations, despite the 
absence of ramA overexpression. These results therefore suggest that ramA 
overexpression is not significant in mediating PxB and colistin resistance compared 
to phoP overexpression. This observation is backed up by the inability of other ramA 
overexpressing strains to survive at higher antibiotic concentrations. This contrasts 
with the previously reported role of ramA overexpression in reducing PxB and 
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Figure 16. MIC of K. pneumoniae Ecl8 w/t and mutant strains and S. Typhimurium 4/74 
w/t and mutant strains to PxB and colistin. MICs are presented as an average of the 
experimentally derived results. Each strain was tested at least once, in duplicate. Error bars 

















colistin susceptibility [1], and might represent a more dominant role for PhoPQ 
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Table 8. MIC of K. pneumoniae Ecl8 w/t and mutant strains and S. Typhimurium 4/74 




















Strains PxB (mg/L) Colistin (mg/L) 
Ecl8 0.1875
2
 0.094 – 0.1875
2
 
Ecl8ΔramA 0.125 – 0.1875
2





















































Table 8. Each strain was tested at least once, in duplicate. For in-text referencing of MIC 
values, the higher MIC is used. 
1
 Strains were tested once, in duplicate; 
2
 strains were 
tested twice, each time in duplicate; 
3
 strains were tested on three occasions, each time in 
duplicate. 
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K. pneumoniae is an increasingly important pathogen worldwide due to the rapid 
emergence and dissemination of MDR strains. MDR K. pneumoniae infection has 
severe ramifications, and is particularly threatening to vulnerable patients, such as 
the elderly or immunocompromised [45]. Recently, there has been an increasing 
interest in the use of the last-line drugs tigecycline and colistin for the treatment of 
MDR K. pneumoniae infection [80, 144-146]. However, resistance to even these 
last-line antimicrobials has begun to emerge, with intrinsic bacterial factors such as 
the RamA and PhoPQ regulators playing a major role [1, 134, 135, 143, 177, 183, 
196-199, 211]. In this report, we have assessed how overexpression of ramA, phoP 
and lpxO genes contributes to tigecycline, PxB and colistin susceptibility. We also 
assessed the role of K. pneumoniae RamA regulation in susceptibility to these drugs 
via inactivation of ramA and RamA-regulated permeability genes: acrAB, tolC, ompC 
and ompF. We were unable to generate phoPQ knockout mutants therefore we 
examined the impact of PhoPQ regulation on polymyxin susceptibility using pre-
existing S. Typhimurium phoPQ knockouts. 
Our findings corroborate with previous studies where ramA overexpression is 
responsible for reduced tigecycline susceptibility in K. pneumoniae [134, 135, 143, 
238], with important roles for RamA-regulated permeability components, including 
the efflux pump AcrAB and TolC and the OM porin OmpF (Figure 9; Table 6). We 
report that chromosomal ramA overexpression mediated by ramR inactivation 
reduces susceptibility to tigecycline. We also show that inactivation of acrAB and 
tolC efflux genes increases susceptibility, consistent with reports of tigecycline 
resistance being mediated by the AcrAB-TolC efflux pump [227, 228, 235-238]. We 
also observed that inactivation of ompF led to an increased tigecycline MIC. 
However, a literature search failed to identify previous reports where inactivated 
ompF was responsible for tigecycline resistance. It has been suggested that 
tigecycline influx into the bacterial cell is in part mediated by the porins OmpF and 
OmpC [239], similar to other tetracyclines [105, 240], and that decreased ompF 
levels contribute to reduced tetracycline susceptibility [118, 241]. Linkevicius et al. 
[239] describe how gene mutations in E. coli affecting LPS heptose biosynthesis, 
which can result in decreased porin expression, leads to reduced tigecycline 
susceptibility. Alterations to LPS, OM stability and porin activity that prevent 
tigecycline influx may consequently limit the drug’s activity and reduce sensitivity. 
This mechanism of reduced cell entry would corroborate our findings, where loss of 
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ompF may prevent tigecycline influx, thereby resulting in the reduced tigecycline 
susceptibility phenotype shown here. In contrast, no effects on tigecycline 
susceptibility were seen in ompC mutants compared to controls. Due to the similar 
tigecycline MICs of acrAB and tolC knockout mutants, we have not managed to 
shed light on which of these genes contributes most to tigecycline susceptibility. It 
would therefore be interesting to assess the effect of acrAB and tolC overexpression 
in an Ecl8ΔramA background; to observe whether tolC or acrAB overexpression can 
reduce susceptibility to tigecycline in the absence of ramA. These potential future 
experiments would help to define whether acrAB and tolC are key components of 
RamA-mediated tigecycline resistance. 
We further demonstrate that overexpressed phoP appears to have no role in 
increasing tigecycline resistance (Figure 9; Table 6). On the other hand, plasmid-
mediated lpxO overexpression in K. pneumoniae Ecl8ΔramR exhibited a 2-fold 
higher tigecycline MIC than Ecl8ΔramR alone, or the vector-only control. However, 
this effect seems dependent on chromosomal ramA overexpression, as 
Ecl8/pAClpxO displayed no susceptibility changes compared to w/t Ecl8 and 
Ecl8/pACYC184. Additionally, in E. coli DH10β, introduction of pAClpxO conferred a 
3-fold and 2-fold reduction in susceptibility compared to the vector-only control and 
w/t Ecl8 respectively (Figure 15; Table 7), implicating lpxO overexpression as a 
factor in tigecycline susceptibility. Tigecycline resistance is typically mediated by 
increased activity of efflux pumps such as AcrAB [227, 228, 235-238], with no 
studies found that reported a role for LpxO or other lipid A modifiers. Tigecycline is a 
derivative of the tetracycline class of antimicrobials; these drugs can cross the OM 
via porins as a cationic complex [240]. Therefore lipid A modifications, which 
neutralise LPS charge and increase OM stability [105, 176, 177, 191], may prevent 
the ability of tigecycline to bind and traverse the OM, perhaps explaining why lpxO 
overexpression reduced tigecycline sensitivity. The effect of lpxO overexpression on 
reducing tigecycline susceptibility is primarily seen in Ecl8ΔramR as opposed to 
Ecl8; this may be explained by the increased efflux and decreased influx mediated 
by ramA overexpression, which we show also contributes to tigecycline resistance, 
and which may amplify the effects of lpxO expression. 
The chromosomal ramA overexpressors Ecl8ΔramR and Ecl8<ramR>Km both 
demonstrated reduced susceptibility to PxB and colistin compared to w/t Ecl8 
(Figure 10; Table 6), thus confirming that ramA overexpression reduces 
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susceptibility to PxB and colistin. Of the RamA-regulated genes tested, 
Ecl8ΔramR<acrAB>Km displayed increased susceptibility to PxB and colistin, 
indicating that acrAB is an important component of RamA-mediated polymyxin 
resistance (Figure 10; Table 6). This corresponds to a previous report  where AcrAB 
was shown to contribute to CAMP resistance [216]. Inactivation of tolC increased 
susceptibility to colistin only in Ecl8; this may indicate that ramA overexpression 
compensates for loss of tolC by increasing expression of other resistance genes, 
such as acrAB, thereby maintaining the polymyxin resistance phenotype. We did not 
detect any difference in susceptibility with ompF or ompC knocked out in either a w/t 
or ramA overexpressing background, indicating that porins play no part in RamA-
mediated polymyxin resistance (Figure 10; Table 6).  
The impact of lpxO overexpression on polymyxin susceptibility was inconclusive, 
with pAClpxO and pBRlpxO in w/t and ramA-overexpressing backgrounds unable to 
reduce susceptibility in MIC experiments compared to w/t Ecl8 and Ecl8ΔramR 
(Figure 10; Table 6). Contrastingly, in E. coli DH10β pAClpxO increased PxB and 
colistin MICs, with DH10β/pAClpxO conferring a minor decrease in susceptibility to 
both agents compared to the vector-only control. Likewise, the colistin survival assay 
displayed a greater relative survival at 0.033 μg/ml for Ecl8/pAClpxO compared to 
Ecl8 and the Ecl8/pACYC184 control (Figure 14). Interestingly, Ecl8ΔramR/pAClpxO 
exhibited lower survival at 0.033 μg/ml colistin than Ecl8/pAClpxO. A similar colistin 
survival percentage between Ecl8/pAClpxO and Ecl8ΔramR/pAClpxO might indicate 
that lpxO is important to ramA-mediated polymyxin resistance; however, we instead 
see the opposite, where lpxO overexpression mediates colistin survival where ramA 
overexpression does not. This was unexpected as PxB and colistin MICs show that 
lpxO overexpression in w/t and ramA overexpressing backgrounds does not reduce 
polymyxin susceptibility, in contrast to chromosomal ramA overexpression (Figure 
10; Table 6). Methodological differences in the way in which MIC experiments and 
RSAs are performed may explain the different results observed, where the high 
survival percentage of Ecl8pAClpxO does not correspond to the low pAClpxO PxB 
and colistin MICs. Taken together, the role of lpxO overexpression in polymyxin 
resistance is unclear due to our conflicting results. Although other studies have 
linked K. pneumoniae lpxO with an important role in polymyxin and CAMP 
resistance [1, 183, 206], they did not assess the effects of lpxO overexpression in 
isolation, and have instead considered its role in the context of transcriptional 
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regulators that control multiple genes. These regulators may therefore mediate 
reduced polymyxin susceptibility via a variety of alternative mechanisms, with lpxO 
potentially playing an accessory role. As a result, repetition of antimicrobial 
susceptibility experiments is necessary to define whether LpxO-mediated lipid A 
modifications are significant to this phenotype; generating knockout lpxO mutants is 
important in order to characterise the functional phenotype resulting from gene loss; 
and antimicrobial binding and permeabilisation assays would be useful to assess if 
the activity of polymyxins or CAMPs is reduced by lpxO overexpression.  
We report that phoP overexpression mediates PxB and colistin resistance 
independently of ramA, due to the greater MIC values of pACphoP strains (ranging 
from 2.6-fold to 4-fold) (Figure10; Table 6) and greater survival at higher antibiotic 
concentrations (Figures 14 and 15) compared to Ecl8ΔramR and Ecl8<ramR>Km. 
We also show that inactivation of the phoPQ locus in S. Typhimurium results in 
substantially increased polymyxin susceptibility (Figure 16; Table 8). PhoPQ 
regulates lpxO in K. pneumoniae, and subsequent LpxO-mediated lipid A 
modifications contribute to polymyxin and CAMP resistance [183, 206]; therefore we 
would expect to see similar polymyxin MIC values between phoP and lpxO 
overexpressing strains. Instead we see substantially higher PxB and colistin MICs 
for pACphoP strains compared to pAClpxO and pBRlpxO strains, which indicates 
that LpxO-mediated lipid A modifications are not essential to phoP-mediated 
polymyxin resistance. The observed role for phoP expression in K. pneumoniae 
polymyxin resistance is significant due to the potential impacts on treating infections. 
The potential for cross-resistance also presents a troublesome mechanism whereby 
polymyxins and host immune factors, such as human LL-37, are able to induce 
PhoPQ [183, 192, 211], resulting in cross-resistance to CAMPs. In our study both 
phoP and ramA overexpression reduced polymyxin susceptibility. Due to the 
previously reported impact of ramA overexpression on reducing both polymyxin and 
LL-37 susceptibility [1], the potential for the involvement of ramA in cross-resistance 
requires further investigation. 
Problems were encountered throughout the project, impacting on time and 
preventing a more thorough investigation of the hypothesis. Therefore the next steps 
of this project must be to repeat MICs and RSAs in order to thoroughly characterise 
target genes, assess the consistency of our findings, and confirm or reject our 
conclusions. One such problem was generating lpxO and phoPQ knockout mutants, 
P a g e  | 89 
 
  
in response to the finding that our original lpxO knockout mutants still retained the 
lpxO gene (Figure 8). Despite using an established protocol [217], we were 
repeatedly unable to genotypically confirm by PCR the absence of the lpxO gene, 
despite observing a KmR phenotype indicating a successful integration of the 
replacement Km cassette into the chromosome. This may have been simply an 
issue with our primers; however replacement primers were purchased and tested 
with no success, and Km primers specific for the cassette were used by other 
laboratory members to confirm successful knockout of other genes using the same 
protocol. The reproducibility of protocols is often a problem in laboratories with 
increasing awareness in the scientific media [242, 243]. In our case, erroneous 
integration of the Km cassette or gene duplication events as environmental 
adaptations are possible occurrences in procedures involving manipulation of 
bacterial genes [244, 245], and may explain the retention of both the lpxO gene and 
a KmR phenotype. Whilst we did not anticipate any gene duplication events due to 
previous reports of successful lpxO and phoPQ deletion [183, 206], the retention or 
duplication of lpxO may also explain the unexpectedly high MICs of our putative 
ΔlpxO mutants to all antimicrobials tested. Similar MICs were not observed with 
other knockout strains tested where the gene of interest was also replaced with a 
Km cassette, suggesting that the high MIC values of Ecl8<lpxO>Km and 
Ecl8ΔramR<lpxO>Km are not an artefact of the Km cassette. The inability to 
generate mutants is unfortunate as assessing the impact of lpxO and phoPQ 
knockout on susceptibility to PxB and colistin, together with the effects of plasmid-
mediated lpxO and phoP overexpression, would allow a much more thorough 
characterisation of their roles. As such, an important next step for this project will be 
to generate these mutants, possibly utilising a different approach in order to 
negotiate the difficulties faced with our exchange protocol.  
Interpreting our findings was also difficult due to the inconsistent and unexpected 
outcomes of our plasmid constructs. For example, the pBR322 control appeared to 
drive a reduction in susceptibility to tigecycline instead of pBRlpxO (Figure 9; Table 
6), whereas the introduction of pACYC184 into Ecl8ΔramR increased susceptibility 
to colistin (Figure 10; Table 6). Furthermore, the inconsistent activity of the 
pACramA, pAClpxO and pBRlpxO constructs might suggest that they were not 
generated correctly, or not transformed appropriately into Ecl8 and Ecl8ΔramR. 
However, pACphoP, constructed in much the same way, demonstrates a very clear 
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resistance phenotype to PxB and colistin incomparable to other tested strains. This 
indicates that the pACphoP construct was successfully generated, and would imply 
that the other constructs were as well.  
Interestingly, pACramA strains did not demonstrate reduced susceptibility to any of 
the antimicrobials tested in spite of the increased MICs of Ecl8ΔramR and 
Ecl8<ramR>Km. Where pACramA strains did exhibit reduced susceptibility, 
observed in tigecycline MICs and PxB and colistin RSAs, this often corresponded to 
similar susceptibility of the pACYC177 vector-only controls, with the common theme 
among less susceptible pACramA and pACYC177 strains being an Ecl8ΔramR 
background. This confirms that ramA overexpression in K. pneumoniae is important 
in reducing tigecycline and polymyxin susceptibility, but implies that our pACramA 
construct was not overexpressing ramA due to the dissimilar phenotypes observed. 
Furthermore, introduction of pACramA into E. coli DH10β failed to reduce 
susceptibility to tigecycline, PxB or colistin, despite George et al. [101] previously 
demonstrating that introduction of ramA from a MDR K. pneumoniae mutant into E. 
coli K12 produced a MDR phenotype identical to the original K. pneumoniae isolate. 
Previous work in our laboratory has also demonstrated that pACramA 
complementation with Ecl8ΔramA returned the susceptibility phenotype to that of w/t 
Ecl8 (Unpublished data). The inability of our pACramA strains to therefore reduce 
susceptibility to tigecycline or polymyxins suggests that an error may have occurred 
somewhere in the process of extracting pACramA and transforming it into Ecl8 and 
Ecl8ΔramR. The KmR phenotype that indicated a successful transformation may 
have been acquired from contamination or selective pressure, leading to the 
assumption that Ecl8/pACramA and Ecl8ΔramR/pACramA were valid. Alternatively, 
plasmid-mediated ramA overexpression may have overwhelmed transformed 
bacteria, potentially causing toxicity and compromising the MDR phenotype. 
6.1. Summary 
Both RamA and PhoPQ regulate the expression of lpxO in K. pneumoniae [1, 183, 
206], whilst LpxO-mediated lipid A modifications are associated with reduced 
susceptibility to the last-line polymyxin drugs and host immune CAMPs [183, 206, 
211]. Herein we have corroborated previous reports that overexpression of lpxO 
reduces susceptibility to PxB and colistin. Confirmation of our findings and our 
hypothesis will require repetition of experiments and further characterisation in the 
future. In fact, whilst we demonstrate a role for ramA in reduced PxB and colistin 
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susceptibility, as reported previously [1], our most convincing findings were that 
overexpression of phoP is the primary driver of reduced susceptibility to both of 
these agents. Due to the increasing reliance on colistin for the treatment of MDR K. 
pneumoniae infections, further investigation into the mechanisms behind phoP-
mediated reduced susceptibility to these drugs is crucial. Furthermore, we also 
report that lpxO overexpression plays a role in reducing tigecycline susceptibility. 
Mutations to LPS biosynthesis genes not including lpxO have been observed to 
reduce tigecycline sensitivity in E. coli [239]; however we are the first to demonstrate 
this phenotype in K. pneumoniae as a result of lpxO overexpression. This has 
implications for the use of this drug in the treatment of MDR K. pneumoniae 
infections, due to the potential for intrinsically generated resistance to develop, and 
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